

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Increased intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity was associated with excessive risks of prediabetes plus diabetes

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057820
Article Type:	Original research
Date Submitted by the Author:	29-Sep-2021
Complete List of Authors:	Xu, Qiaoyan Zhang, Junfeng Wang, Shunqin chen, ning; Xiamen branch, Zhongshan hospital, Fudan University, Xiamen, China, Endocrinology Lai, Fangfang Lin, Mingzhu; Department of Endocrinology and Diabetes Liu, Yongwen; Department of Nursing Zhang, Wei Liu, Changqin; The First Affiliated Hospital of Xiamen University, Department of Endocrinology and Diabetes li, Zhibin; The First Hospital of Xiamen,
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Adult gastroenterology < GASTROENTEROLOGY, Hepatology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Manuscript Type: Original Article

Increased intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity was associated with excessive risks of prediabetes plus diabetes

Qiaoyan Xu^{a#}, Junfeng Zhang^{a#}, Shunqin Wang^{b#}, Ning Chen^{c#}, Fangfang Lai^a,

Mingzhu Lin^d, Yongwen Liu^e, Wei Zhang^f, Changqin Liu^{d*}, Zhibin Li^{g*}

^a Lianqian Community Health Service Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

^b Key laboratory of Neonatal Diseases, Children's Hospital of Fudan University Xiamen Branch & Xiamen Children's Hospital, Xiamen, China

^c Department of Endocrinology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, China

^d Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China

^e Department of Nursing, The First Affiliated Hospital of Xiamen University, Xiamen, China

^f Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen, China

^g Epidemiology Research Unit, Translational Medicine Research Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

Running title: Association of IHTG content in MHAO with prediabetes

Word count: 3249

1
2
3
4 **Number of tables and figures: 4**
5

6 # These authors contribute to this work equally.
7

8
9 * Corresponding authors and persons to whom reprint requests should be addressed:
10

11 Dr. Changqin Liu
12

13
14 Department of Endocrinology and Diabetes,
15

16
17 The First Affiliated Hospital, Xiamen University & The Teaching Hospital of Fujian Medical
18
19 University
20

21
22 No.55 Zhenhai Road, Xiamen 361003, China.
23

24
25 Phone: +86-592-2137610;
26

27
28 Fax: +86-592-2137557;
29

30
31 Email: liuchangqin@xmu.edu.cn
32

33 &
34

35 Dr. Zhibin Li
36

37
38 Epidemiology Research Unit,
39

40
41 Translational Medicine Research Center,
42

43
44 The First Affiliated Hospital, Xiamen University
45

46
47 No.55 Zhenhai Road, Xiamen 361003, China
48

49
50 Phone: +86-592-2137364;
51

52
53 Fax: +86-592-2137557;
54

55
56 Email: zhibinli33@hotmail.com
57
58
59
60

1
2
3
4 ABSTRACT

5
6 **Objectives** We aimed to evaluate the association of intrahepatic triglyceride (IHTG) content
7
8
9 in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes
10
11 plus diabetes.
12

13
14 **Design** Cross-sectional survey.
15

16
17 **Setting** Lianqian community, the First Affiliated Hospital of Xiamen University, Xiamen,
18
19 China.
20

21
22 **Participants** Among 1,523 community-living healthy adults aged 40 years or older with
23
24 abdominal obesity recruited at baseline, 428 subjects who underwent intrahepatic triglyceride
25
26 (IHTG) content measurement selected at random chose to participate.
27
28

29
30 **Outcome measures** metabolically healthy abdominal obesity (MHAO), metabolically
31
32 unhealthy abdominal obesity (MUAO), prediabetes, and diabetes.
33
34

35
36 **Results** Nonalcoholic fatty liver disease (NAFLD) were diagnosed as 203 (69.1%) in MHAO
37
38 and 121 (90.3%) in metabolically unhealthy abdominal obesity (MUAO) ($p<0.001$). The
39
40 prevalence rates of prediabetes plus diabetes were 81.1%, 88.8% and 90.9% across the
41
42 tertiles of IHTG content ($p=0.037$). Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-
43
44 NAFLD) were independently associated with increased risks of prediabetes plus diabetes, the
45
46 adjusted ORs (95%CI) were 10.90 (3.15-37.69, $p<0.001$) and 3.02 (1.47-6.20, $p=0.003$),
47
48 respectively. Higher IHTG content was significantly associated with increased risk of
49
50 prediabetes plus diabetes with the adjusted OR (95%CI) of per SD increase of IHTG content
51
52 of 1.62 (1.07-2.46, $p=0.024$). And there was a significantly positive trend between increasing
53
54 categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes (trend test
55
56
57
58
59
60

1
2
3
4 p-value =0.011). Stratified analyses showed similar results on the associations of NAFLD
5
6 and IHTG content with risks of prediabetes plus diabetes for subjects with MHAO but not for
7
8 those with MUAO.
9

10
11 **Conclusions:** NAFLD and higher IHTG content were independently associated with
12
13 increased risks of prediabetes plus diabetes in MHAO subjects. NAFLD or quantity of liver
14
15 fat should be considered as additional criterion when defining and diagnosing MHO.
16
17 Screening of NAFLD and intervention to reduce liver fat should be strengthened even for the
18
19 seemingly healthy obese.
20
21
22
23

24 **Keywords:** metabolically healthy obesity; intrahepatic triglyceride; nonalcoholic fatty liver
25
26 disease; prediabetes; diabetes;
27
28
29
30
31

32 **Strengths and limitations of this study**

- 34
35 ➤ There was a significantly positive trend of higher prevalence of diabetes plus diabetes
36
37 with increasing categories of tertiles of IHTG content.
- 38
39 ➤ Both NAFLD and higher IHTG content were independently associated with increased
40
41 risks of prediabetes plus diabetes in MHAO subjects.
- 42
43 ➤ The current study indicate that quantity of liver fat or NAFLD should be considered as
44
45 additional criterion when defining and diagnosing MHO.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The global prevalence of diabetes in 2019 was estimated to be 9.3% (463 million people) and would rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045, which has quadrupled during the past three decades and has contributed a heavy public health burden worldwide [1-3]. Obesity has been well documented to contribute a broad array of chronic non-communicable diseases, including diabetes, hypertension, coronary heart disease, chronic kidney disease and certain sites of cancer [4-6]. A subgroup of obese individuals who are devoid of obesity-related metabolic complications, such as diabetes and atherosclerosis, arise the concept of metabolically healthy obese (MHO) [7-9]. However, there is no unique definition and diagnose criteria for MHO by now. For example, some defined MHO when two or fewer of the 4 criteria of metabolism syndrome [10] for those obese subjects while others defined as none of them [11], which made evidence on the association of MHO with diabetes was limited and controversial [12].

Nonalcoholic fatty liver disease (NAFLD) is well documented to be associated with risk of diabetes [13], while NAFLD or excessive fat accumulation in liver which usually occurs simultaneously when obesity happens has not been considered as additional criterion for MHO. Therefore, little evidence is available on the risk of NAFLD or liver fat with diabetes for those with MHO. In the present study with 428 community-living Chinese adults with abdominal obesity, we mainly aimed to evaluate associations of intrahepatic triglyceride (IHTG) content and NAFLD in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes plus diabetes.

MATERIALS AND METHODS

Study design and subjects

Details on study design and subjects recruitment have been described previously [14,15].

Briefly, 1,523 community-living healthy adults aged 40 years or older with abdominal obesity (waist circumference greater than 90 cm for men and 80 cm for women) living in Lianqian community, Xiamen, China were recruited at baseline of the cohort study in 2011. Of them, a random sample of 428 subjects who underwent intrahepatic triglyceride (IHTG) content measurement was left for the present analysis. This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China) and conducted according to the principles of the Declaration of Helsinki.

Written informed consent was obtained from each participant.

Measurements

For each subject, face-to-face interview was conducted to collect socio-demographic status, lifestyle habits, present and previous history of health and medications. Subjects were excluded if they drank regularly with alcohol consumption ≥ 140 g/week for men or ≥ 70 g/week for women, had cancer, or received current treatment with systemic corticosteroids, biliary obstructive diseases, acute or chronic virus hepatitis, drug-induced liver diseases, total parenteral nutrition, autoimmune hepatitis, Wilson's disease, known hyperthyroidism or hypothyroidism. Subjects underwent weight, height and waist circumference measurements by using a calibrated scale after removing shoes and heavy clothes. Body mass index (BMI) was calculated as weight in kilograms divided by height in squared meters. Arterial blood

1
2
3
4 pressure (BP) was measured with a mercury sphygmomanometer after sitting for at least 15
5
6 minutes.
7
8
9

10
11 Blood samples were obtained after 12-hour fasting and 75-g oral glucose tolerance test were
12
13 conducted for each subject. All biochemical measurements were tested in the central
14
15 laboratory of the First Affiliated Hospital, Xiamen University. Plasma glucose and serum
16
17 lipid profiles, including triglyceride (TG), total cholesterol (TC), and high-density lipoprotein
18
19 cholesterol (HDL-C) were determined on a HITACHI 7450 analyzer (HITACHI, Tokyo,
20
21 Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's
22
23 formula. Fasting plasma glucose (FPG) and 2-hour plasma glucose (2-h PG) concentrations
24
25 were measured by the hexokinase method and HbA1c by the Bio-Rad Variant Hemoglobin A1c
26
27 assay.
28
29
30
31
32
33
34
35
36
37

38 **Ultrasonography and definition of non-alcoholic fatty liver disease**

39
40 Hepatic ultrasonography scanning was performed by an experienced radiologist using GE
41
42 LOGIQ P5 scanner (GE Healthcare, Milwaukee, USA) with a 4-MHz probe, who was
43
44 blinded to the subjects' health status. Hepatic steatosis was diagnosed on the basis of
45
46 characteristic sonographic features, including hepatorenal echo contrast, liver parenchymal
47
48 brightness, deep beam attenuation, and vessel blurring [16]. The definition of NAFLD was
49
50 based on hepatic ultrasonography diagnosis of hepatic steatosis without excessive alcohol
51
52 consumption, viral or autoimmune liver disease.
53
54
55
56
57
58
59
60

Intrahepatic triglyceride (IHTG) content measurement

IHTG content was determined by an experienced radiologist using Magnetic resonance spectroscopy (^1H MRS, 3.0-T Avanto, Siemens AG, Erlangen, German). Images of a sagittal, coronal and axial cube of a 2 cm^3 volume in the right lobe of liver was acquired.

Quantification of the spectra (water and methylene resonances) was performed as described previously [17]. Areas of resonance from water protons and methylene groups in fatty acid chains were obtained with a time-domain non-linear fitting routine by using Syngo MR B15V software (Siemens AG). The percentage of IHTG content was calculated as the ratio of the area under the resonance of peak for methylene groups in fatty acid chains of IHTG and the combined area under the resonance peaks for both methylene groups and water.

Definition of metabolically healthy abdominal obesity

Abdominal obesity was defined as WC $\geq 90\text{cm}$ for men and 80cm for women [18]. All subjects in the present study were abdominal obesity which was considered as one of the recruitment criterion. Subjects were defined as metabolically healthy abdominal obesity (MHAO) if two or fewer of the following criteria were met: ①systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg; ②fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L); ③TG ≥ 150 mg/dL (1.7 mmol/L); ④HDL cholesterol < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.30 mmol/L) in women [19,20]. Otherwise, subjects meeting 3 or more of the criteria were defined as metabolically unhealthy abdominal obesity (MUAO). Therefore, all subjects in the present study were dichotomized as either MHAO or MUAO.

Definitions of diabetes and prediabetes

According to American Diabetes Association (ADA) 2020 criteria, diabetes was defined as (1) a self-reported history of diabetes previously diagnosed by health care professionals; (2) FGP ≥ 126 mg/dL (7.0mmol/L); (3) 2-hour plasma glucose (2-h PG, OGTT) ≥ 200 mg/dL (11.1mmol/L); or (4) HbA1c $\geq 6.5\%$. Prediabetes were defined as (1) FPG levels between 100 mg/dL (5.6mmol/L) and 125 mg/dL (6.9mmol/L), (2) 2-h PG levels between 140 mg/dL (7.8mmol/L) and 199 mg/dL (11.0mmol/L), or (3) HbA1c between 5.7% and 6.4% in participants without a prior diabetes diagnosis [21].

Statistical analyses

Data were presented as the mean \pm standard deviation for continuous variables or number and percentage for categorical variables. Skewness and kurtosis tests for continuous variables were conducted and found them followed approximation of normal distributions. Differences between subjects categorized by MHAO and tertiles of IHTG content were analyzed using one-way ANOVA for continuous variables and chi-square test for categorical variables. Bar graphs showing prevalence rates of diabetes, prediabetes and normal glucose test (NGT) were made by MHAO (v.s. MUAO) and tertiles of IHTG content.

Multivariable logistic regression models were used to calculate the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of abdominal obesity (MUAO v.s. MHAO), NAFLD (yes v.s. no) and IHTG content (both the originally continuous values and the tertiles categories) for prediabetes plus diabetes with adjustment for potential confounders (including age, sex,

1
2
3
4 educational level, smoking and drinking habits, regular physical exercise, BMI, systolic and
5
6 diastolic BP, triglyceride, total cholesterol, HDL- and LDL-cholesterol and serum uric acid).
7
8
9 And multivariable logistic regression analyses stratified by MHAO and MUAO groups were
10
11 further conducted. All p-values were two-sided and p-value <0.05 was considered statistically
12
13 significant. All statistical analyses were performed using Stata14.0 (StatCorp, College
14
15 Station, TX).
16
17
18
19
20
21

22 **Patient and public involvement**

23
24 There were no funds or time allocated for patient and public involvement.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Prevalence of diabetes and prediabetes stratified by MHAO and tertiles of IHTG content

Among the 428 subjects with abdominal obesity, MHAO and MUAO were identified on 294 (68.7%) and 134 (31.3%) subjects. Of them, 46 (10.8%), 326 (76.2%) and 56 (13.1%) were diagnosed as diabetes, prediabetes and normal glucose tolerance (NGT), respectively. There was a significantly positive trend between increasing tertiles of IHTG content and higher prevalence of prediabetes plus diabetes (81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p=0.037$)). Figure 1 showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MHAO subjects were 7.1% and 67.3%, 10.2% and 74.5%, 10.2% and 77.6% for the Tertile 1, Tertile 2 and Tertile 3, respectively ($p\text{-value}>0.05$). But there was a significantly positive trend of higher prevalence of diabetes plus diabetes with increasing categories of tertiles of IHTG content ($p=0.039$). Figure 2 showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MUAO subjects were 8.9% and 86.7%, 8.9% and 88.9%, 25.0% and 72.7% for Tertile 1, Tertile 2 and Tertile 3, respectively. Table 1 also showed MUAO subjects had significantly higher prevalence of prediabetes and prediabetes plus diabetes than MHAO subjects (both $p\text{-values}<0.05$).

Demographic and clinical characteristics stratified MHAO and tertiles of IHTG content

For all the 428 subjects, the means (\pm SD) of age were 53.6 (\pm 6.5) years for women ($n=319$, 74.5%) and 53.2 (\pm 7.1) years for men ($n=109$, 25.5%) ($p=0.592$). Table 1 showed differences of demographics, life style habits and clinical characteristics stratified by MHAO and tertiles

1
2
3
4 of IHTG content. For 294 MHAO subjects, with increasing categories of the tertiles of IHTG
5
6 content (from tertile 1, tertile 2 to tertile 3), subjects were more likely to be male and had
7
8 significantly higher levels of indices of obesity (BMI, waist circumference), diastolic BP,
9
10 significantly higher levels of indices of obesity (BMI, waist circumference), diastolic BP,
11
12 triglyceride, HbA1c, serum uric acid as well as higher prevalence of NAFLD and
13
14 significantly lower level of HDL-C. As for 134 MUAO subjects, increasing categories of the
15
16 tertiles of IHTG content were significantly related to higher prevalence of NAFLD and serum
17
18 uric acid levels. Furthermore, Table 1 showed that, compared to subjects with MHAO, those
19
20 with MUAO had significantly increased age, IHTG content, prevalence of NAFLD, systolic
21
22 and diastolic BP, triglyceride, total cholesterol, FPG, 2-h PG, HbA1c, serum uric acid and
23
24 significantly lower level of HDL-C.
25
26
27
28
29
30
31

32 **Associations of MHAO, NAFLD and IHTG content with prediabetes plus diabetes for** 33 **all subjects** 34 35 36

37 Table 2 showed that, for all subjects, both MUAO (v.s. MHAO) and NAFLD (yes v.s. no)
38
39 were independently associated with increased risk of prediabetes plus diabetes, and the
40
41 adjusted ORs (95% CIs) were 10.90 (3.15-37.69, $p < 0.001$) and 3.02 (1.47-6.20, $p = 0.003$),
42
43 respectively. Higher IHTG content was significantly associated with increased risk of
44
45 prediabetes plus diabetes with the adjusted OR (95% CI) of per SD increase of IHTG content
46
47 of 1.62 (1.07-2.46, $p = 0.024$). With the tertile 1 of IHTG content as the reference, the tertile 3
48
49 showed significantly higher risk of prediabetes plus diabetes (adjusted OR (95% CI): 3.13
50
51 (1.28-7.61), $p = 0.012$). And there was a significantly positive trend of increasing categories of
52
53 IHTG content tertiles with excessive risk of prediabetes plus diabetes (trend test: $p = 0.011$).
54
55
56
57
58
59
60

1
2
3
4 There was no significant interaction between MHAO with either NAFLD or tertiles of IHTG
5
6 content for risk of prediabetes plus diabetes (both p-values>0.05).
7
8
9

10 11 **Stratified analyses on associations of NAFLD and IHTG content with prediabetes plus** 12 13 **diabetes by MHAO & MUAO** 14 15

16
17 Multivariable logistic regression analyses stratified by MHAO and MUAO separately were
18
19 conducted. For MHAO subjects, NAFLD was independently associated with increased risk of
20
21 prediabetes plus diabetes (adjusted OR (95%CI): 2.65 (1.25-5.60), p=0.011). Per SD increase
22
23 of IHTG content was marginally associated with excessive risk of prediabetes plus diabetes
24
25 with the adjusted OR (95%CI) of 1.55 (1.00-2.40, p=0.051). Compared with the tertile 1 of
26
27 IHTG content, both the tertile 2 and tertile 3 groups showed significantly increased risks of
28
29 prediabetes plus diabetes with the adjusted ORs (95%CI) of 2.31 (1.03-5.17, p=0.042) and
30
31 2.81 (1.14-6.90, p=0.024), respectively. And there was also a significantly positive trend
32
33 between increasing categories of IHTG content tertiles and excessive risk of prediabetes plus
34
35 diabetes (trend test: p=0.021). For MUAO subjects, neither NAFLD nor IHTG content was
36
37 found to be significantly associated with risk of prediabetes plus diabetes.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

In the present study of 428 subjects with abdominal obesity, 294 (68.7%) and 134 (31.3%) were identified as MHAO and MUAO, respectively. For all subjects, the prevalence rates of prediabetes plus diabetes were 81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p=0.037$). Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-NAFLD) were independently associated with increased risks of prediabetes plus diabetes. Furthermore, higher IHTG content was significantly associated with increased risk of prediabetes plus diabetes with the adjusted OR (95%CI) of per SD increase of IHTG content of 1.62 (1.07-2.46, $p=0.024$), and there was a significantly positive trend between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes. Stratified analyses showed similar results for subjects with MHAO but not for those with MUAO.

The concept of MHO has been established for a subgroup of obese subjects who do not exhibit metabolic and cardiovascular complications at a given time point, such as diabetes and atherosclerosis, for a few decades [22,23]. Compared to subjects with MUO, those with MHO are characterized by lower liver and visceral fat, higher subcutaneous leg fat, greater cardiorespiratory fitness, physical activity and insulin sensitivity, lower levels of inflammation, and normal adipose tissue function [24]. However it could be debated whether MHO predicts the risk of diabetes compared with metabolically healthy normal weight or MUO. Hinnouho GM et al, based on the Whitehall II cohort study, found a significantly decreased risk for MHO compared with metabolically unhealthy obesity (MUO) (HR=1.98 (MUO v.s. MHO), 95% CI: 1.39–2.83) [25]. The present study found similar results that

1
2
3
4 MUAO was significantly associated with increased risk of prediabetes plus diabetes
5
6 compared with MHAO but with a much higher adjusted OR(95%CI) (10.90 (3.15-37.69)).
7

8
9 Hinnouho GM et al and others further found that MHO showed a significant increased risk of
10
11 T2DM incidence compared with metabolically healthy normal weight [25-27]. We cannot
12
13 evaluate the risk of MHAO on diabetes compared with metabolically healthy normal weight
14
15 since all the subjects in the present study were central obese and none of them could be
16
17 classified as metabolically healthy or unhealthy normal weight. And because we had a
18
19 relatively small sample size, we might find the adjusted OR was much higher than those from
20
21 other [25-27].
22
23
24
25
26
27
28
29

30 MHO is generally characterized by lower liver fat; but little evidence is available on
31
32 differences of NAFLD prevalence or liver fat content between MHO and MUO. In the
33
34 present study, we found subjects with MUO, compared to those with MHO, showed
35
36 significantly higher prevalence of NAFLD (90.3% v.s. 69.1%) and IHTG content (16.3±9.5
37
38 v.s. 12.3±9.5%) (both p-values<0.001). Our findings indicated that, even for those with
39
40 MHO, presence of NAFLD and IHTG content are still common and high. Meanwhile MHO
41
42 is commonly identified based on the presence of obesity and metabolic syndrome, neither
43
44 NAFLD nor liver fat content has been considered as an additional criterion when defining
45
46 and diagnosing MHO. Therefore, our findings implied that screening of NAFLD and
47
48 intervention to reduce IHTG content for those seemly healthy obese should be strengthened.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

1
2
3
4 prevalence [28]. The present study expand the positive association of NAFLD to risk of
5
6 prediabetes plus diabetes for all subjects as well as for those with MHAO with the adjusted
7
8 ORs (95%CI) of 3.02 (1.47-6.20) and 2.65 (1.25-5.60) (both p-values<0.05), respectively.
9
10
11 NAFLD has been generally diagnosed by hepatic ultrasonography scanning, which is
12
13 considered to be unreliable and difficult to use in obese subjects [29,30]. Therefore, we
14
15 conducted IHTG content measurement by using magnetic resonance spectroscopy to quantify
16
17 more precisely the extent of liver fat in these abdominal obese subjects. And we found that
18
19 IHTG content was significantly associated with increased risk of prediabetes plus diabetes
20
21 with the adjusted OR (95%CI) of per SD increase of IHTG content of 1.62 (1.07-2.46,
22
23 p=0.024). Moreover, we found a significantly positive trend between increasing categories of
24
25 IHTG content tertiles and excessive risks of prediabetes plus diabetes. Our results on the
26
27 association between IHTG content and risks of prediabetes plus diabetes might account for
28
29 possibly a novel finding for the present study, since little evidence was available on
30
31 association between the relatively precise quantity of liver fat and risk of diabetes [31,32].
32
33
34
35
36
37
38
39
40
41
42

43 We further conducted stratified analyses on the associations of IHTG content with risk of
44
45 prediabetes plus diabetes for subjects with MHAO and MUAO separately. For those with
46
47 MHAO, the association of IHTG content with risk of prediabetes plus diabetes was
48
49 marginally significant, and the adjusted OR (95%CI) of per SD increase of IHTG content was
50
51 1.55 (1.00-2.40, p=0.051). With the first tertile of IHTG content as the reference group, the
52
53 adjusted ORs (95%CI) of risks of prediabetes plus diabetes for the 2nd and 3rd tertiles were
54
55 2.31 (1.03-5.17) and 2.81 (1.14-6.90) (both p-values<0.05), respectively. The positive trend
56
57
58
59
60

1
2
3
4 between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus
5
6 diabetes was also statistically significant for the subgroup with MHAO (trend test p-
7
8 value<0.05). Our findings implied that increased intrahepatic triglyceride content was
9
10 associated with excessive risk of prediabetes and diabetes even for MHO subjects. To the
11
12 best of our knowledge, we were probably the first to find the positive associations of IHTG
13
14 content with risks of diabetes and prediabetes for MHAO subjects. The reason for non-
15
16 significant results for MUAO subgroups may be due to the relatively small sample size of
17
18 subjects with MUAO (n=134).
19
20
21
22
23
24
25
26

27 NAFLD and liver fat quantity has not been currently considered in the definitions and
28
29 diagnose criteria of MHO [24], although liver is one of the main parts of fat accumulation
30
31 when obesity occurs. The present study found that around 69% of subjects with MHAO were
32
33 diagnosed as NAFLD. Most importantly, even for these apparently healthy obese individuals,
34
35 NAFLD and higher IHTG content were both significantly associated with increased risks of
36
37 prediabetes plus diabetes. Therefore, our findings implied that the current criteria of MHO
38
39 may not be appropriate, and NAFLD or quantity of liver fat should be considered as
40
41 additional criterion when defining and diagnosing MHO if more evidence could prove our
42
43 findings in future, especially from the prospective cohort studies with larger sample sizes.
44
45
46
47
48
49

50 A few limitations of the present study should be recognized when generalizing our findings to
51
52 other populations. Firstly, all subjects were abdominally obese and were not randomly
53
54 sampled from their living communities; therefore we could not assess the effect of MHAO as
55
56 compared with metabolically healthy non-obesity and we might also under-estimate the true
57
58
59
60

1
2
3
4 associations of MHAO as compared with MUAO on risks of prediabetes plus diabetes.
5

6 Secondly, the present analyses were based on the baseline information of our ongoing cohort
7
8 study, therefore we cannot determine the temporal sequence among MHAO and prediabetes
9
10 plus diabetes. Thirdly, our sample size was small, especially for the MUAO subgroup and we
11
12 may not have enough power to determine their true associations. On the other hand, we still
13
14 have some strengths in the present study. For example, we used IHTG content by magnetic
15
16 resonance spectroscopy, which was relatively more precise measurement of liver fat. And we
17
18 were probably the first to find the positive associations of IHTG content with risks of
19
20 diabetes and prediabetes, especially for subjects with MHAO.
21
22
23
24
25
26
27
28
29

30 **CONCLUSIONS**

31
32 NAFLD were diagnosed in 69% of MHAO and 90% of MUAO subjects, and the prevalence
33
34 rates of prediabetes plus diabetes were linearly increased across the tertiles of IHTG content.
35
36 NAFLD and higher IHTG content were independently associated with increased risks of
37
38 prediabetes plus diabetes for all subjects as well as for the MHAO subgroups. Therefore, our
39
40 findings imply that NAFLD or quantity of liver fat should be considered as additional
41
42 criterion when defining and diagnosing MHO. Furthermore, screening of NAFLD and
43
44 intervention to reduce liver fat should be strengthened even for the seemingly healthy obese
45
46
47
48
49
50
51 subjects.
52
53
54
55
56
57
58
59
60

Declarations

Acknowledgements

This study was completed with the assistance of the Lianqian community health service center, Xiamen, China. And we are grateful to all the subjects for their participation.

Author contributions

Q.X., J.Z., S.W., N.C. and Z.L. performed the statistical analysis and wrote the manuscript; M.L. and Y.L. participated in the data collection; F.L. and W.Z. contributed to discussion; C.L., N.C., S.W. and J.Z. participated in the design of the study and edited the manuscript.

C.L. and Z.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This study was supported by the grants from National Key R&D Program of China (No. 2017YFC0907100), Natural Science Foundation of China (No. 81870611), Open project of State Key Laboratory of Cellular Stress Biology, and Xiamen University (No. SKLCSB2019KF004).

Conflict of interest statement

No potential conflict of interest relevant to this article is declared.

Ethical approval

This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China) (number/ID of the obtained ethics approval:

1
2
3
4 2011YLS-013) and conducted according to the principles of the Declaration of Helsinki.
5

6 Written informed consent was obtained from each participant.
7

8
9 **Data availability**

10
11 The datasets generated during and/or analyzed during the current study are available from the
12
13
14 corresponding author upon reasonable request.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

- [1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* 2019;157:107843.
- [2]. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018;14(2):88-98.
- [3] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017;389(10085):2239-51.
- [4] Legler J, Fletcher T, Govarts E, et al. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. *J Clin Endocrinol Metab* 2015;100(4):1278-88.
- [5] Collaborators GBDO, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017;377(1):13-27.
- [6] Prospective Studies C, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009;373(9669):1083-96.
- [7] Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. *Am J Clin Nutr* 1956;4(1):20-34.
- [8] Sims EA. Are there persons who are obese, but metabolically healthy? *Metabolism* 2001;50(12):1499-504.
- [9] Stefan N, Haring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. *Lancet Diabetes Endocrinol* 2013;1(2):152-62.
- [10] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint

- 1
2
3
4 interim statement of the International Diabetes Federation Task Force on Epidemiology
5
6 and Prevention; National Heart, Lung, and Blood Institute; American Heart Association;
7
8
9 World Heart Federation; International Atherosclerosis Society; and International
10
11 Association for the Study of Obesity. *Circulation* 2009;120(16):1640-5.
12
13
14 [11] Zhao Y, Qin P, Sun H, et al. Metabolically healthy general and abdominal obesity are
15
16 associated with increased risk of hypertension. *Br J Nutr* 2020;123(5):583-91.
17
18
19 [12] Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type
20
21 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15(6):504-15.
22
23
24 [13] Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel
25
26 cardiometabolic risk factor for type 2 diabetes and its complications. *J Clin Endocrinol*
27
28 *Metab* 2013;98(2):483-95.
29
30
31 [14] Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in
32
33 obese Chinese adults. *PLoS One* 2014;9(4):e94235.
34
35
36 [15] Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic
37
38 triglyceride contents in obese adults. *J Hepatol* 2013;59(3):557-62.
39
40
41 [16] Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty
42
43 liver disease: an updated and revised edition. *Zhonghua Gan Zang Bing Za Zhi*
44
45 2010;18(3):163-6
46
47
48 [17] Frimel TN, Deivanayagam S, Bashir A, et al. Assessment of intrahepatic triglyceride
49
50 content using magnetic resonance spectroscopy. *J Cardiometab Syndr* 2007;2(2):136-8.
51
52
53 [18] Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C.
54
55 Predictive values of body mass index and waist circumference for risk factors of certain
56
57
58
59
60

- 1
2
3
4 related diseases in Chinese adults--study on optimal cut-off points of body mass index and
5
6 waist circumference in Chinese adults. *Biomed Environ Sci* 2002;15(1):83-96.
7
8
- [19] Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide
9
10 definition. *Lancet* 2005;366(9491):1059-62.
11
12
- [20] Fingeret M, Marques-Vidal P, Vollenweider P. Incidence of type 2 diabetes,
13
14 hypertension, and dyslipidemia in metabolically healthy obese and non-obese. *Nutr*
15
16 *Metab Cardiovasc Dis* 2018;28(10):1036-44.
17
18
19
- [21] American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical
20
21 Care in Diabetes-2020. *Diabetes Care* 2020;43(Suppl 1):S14-S31.
22
23
24
- [22] Stefan N, Haring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit
25
26 in obesity treatment? *Lancet Diabetes Endocrinol* 2018;6(3):249-58.
27
28
29
- [23] Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of
30
31 metabolically benign obesity in humans. *Arch Intern Med* 2008;168(15):1609-16.
32
33
34
- [24] Blüher M. Metabolically Healthy Obesity. *Endocr Rev* 2020;41(3): 405–420
35
36
37
- [25] Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the
38
39 risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur*
40
41 *Heart J* 2015;36(9):551-9.
42
43
44
45
46
- [26] Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence
47
48 in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev*
49
50 2020;36(1):e3202.
51
52
53
54
- [27] Gaita D, Mosteoru S. Metabolically healthy versus unhealthy obesity and risk for
55
56 diabetes mellitus and cardiovascular diseases. *Cardiovasc Endocrinol* 2017;6(1):23-26.
57
58
59
60

- 1
2
3
4 [28] Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2
5
6 diabetes via inducing insulin resistance: Association and path analyses. *Cytokine*
7
8
9 2018;108:145-50.
10
11
12 [29] Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of
13
14 hepatic steatosis in morbidly obese patients. *Obes Surg* 2004;14(5):635-7.
15
16
17 [30] Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of
18
19 ultrasonography for the detection of fatty liver: a meta-analysis. *Hepatology*
20
21
22 2011;54(3):1082-90.
23
24
25 [31] Kramer H, Pickhardt PJ, Kliewer MA, et al. Accuracy of Liver Fat Quantification With
26
27 Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR
28
29 Spectroscopy. *AJR Am J Roentgenol* 2017;208(1):92-100.
30
31
32
33 [32] Dong Z, Luo Y, Cai H, et al. Noninvasive fat quantification of the liver and pancreas
34
35 may provide potential biomarkers of impaired glucose tolerance and type 2 diabetes.
36
37
38 *Medicine (Baltimore)* 2016;95(23):e3858.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.

Figure 2. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.

Table Legends

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Variables	MHAO (n=294, 68.7%)				MUAO (n=134, 31.3%)				P-value §
	Tertile 1	Tertile 2	Tertile 3	P-value	Tertile 1	Tertile 2	Tertile 3	P-value	
Demographics & life style									
N (%)	98 (33.3%)	98 (33.3%)	98 (33.3%)		45 (33.6%)	44 (32.8%)			
Male gender (n, %)	12 (12.4%)	27 (27.6%)	30 (30.6%)	0.005*	11 (24.4%)	12 (27.3%)		0.347	0.160
Age (years)	52.8±6.5	53.6±6.6	52.4±6.8	0.422	54.8±6.1	44.1±7.5	55.0±6.0	0.821	0.014*
Low educational attainment, (n, %)	61 (62.2%)	48 (49.0%)	51 (52.0%)	0.241	30 (66.7%)	27 (61.4%)		0.110	0.090
Ever smoking (n, %)	16 (16.3%)	25 (25.5%)	23 (23.5%)	0.262	9 (20.0%)	11 (25.0%)		0.828	0.753
Ever drinking (n, %)	8 (8.2%)	13 (13.3%)	15 (15.3%)	0.291	2 (4.4%)	4 (9.1%)		0.216	0.317
Regular physical exercise (n, %)	34 (34.7%)	42 (42.9%)	32 (32.7%)	0.292	13 (28.9%)	10 (22.7%)		0.296	0.165
Clinical characteristics									
IHTG content (%)	4.10±1.63	9.64±1.97	23.25±8.47	<0.001†	6.86±2.44	14.54±2.91	27.68±6.21	<0.001†	<0.001†
NAFLD (n, %)	34 (34.7%)	75 (76.5%)	94 (95.9%)	<0.001†	35 (77.8%)	42 (93.3%)	44 (100.0%)	<0.001†	<0.001†
BMI (kg/m ²)	26.2±2.5	27.2±2.5	28.3±2.7	<0.001†	27.3±2.5	27.7±3.5	28.1±2.8	0.485	0.121
Waist circumference (cm)	90.7±5.1	93.5±6.1	96.0±7.1	<0.001†	94.0±5.3	93.7±7.8	95.3±6.8	0.518	0.158
Systolic blood pressure (mmHg)	125.6±17.3	130.6±17.5	129.5±15.7	0.095	139.8±12.4	140.9±15.3	143.4±12.6	0.451	<0.001†
Diastolic blood pressure (mmHg)	74.0±10.0	77.8±9.8	78.4±9.7	0.004*	82.7±10.7	83.7±9.4	85.2±8.3	0.482	<0.001†
Triglyceride (mmol/L)	1.22±0.57	1.56±0.82	1.89±0.98	<0.001†	2.53±1.26	3.32±1.90	2.84±1.52	0.062	<0.001†
Total cholesterol (mmol/L)	5.80±1.03	5.81±0.95	5.95±1.05	0.487	6.18±1.43	6.13±1.27	6.02±0.94	0.823	0.024*
HDL-cholesterol (mmol/L)	1.50±0.26	1.39±0.29	1.37±0.25	0.003*	1.20±0.19	1.14±0.22	1.18±0.20	0.401	<0.001†
LDL-cholesterol (mmol/L)	3.75±0.95	3.72±0.79	3.75±1.01	0.973	3.83±1.30	3.50±1.41	3.56±0.84	0.391	0.297

Blood uric acid ($\mu\text{mol/L}$)	322.9 \pm 71.5	359.8 \pm 83.6	378.2 \pm 98.1	<0.001 [†]	348.3 \pm 84.2	321.6 \pm 90.9	426.0 \pm 108.7	<0.001 [†]	0.001*
Fasting plasma glucose (mmol/L)	5.56 \pm 0.46	5.55 \pm 0.54	5.54 \pm 0.51	0.967	5.85 \pm 0.44	5.98 \pm 0.45	5.94 \pm 0.42	0.338	<0.001 [†]
2-h PG (OGTT, mmol/L)	7.42 \pm 2.52	7.51 \pm 1.86	7.87 \pm 1.88	0.285	8.04 \pm 1.91	8.09 \pm 1.72	8.87 \pm 2.13	0.082	<0.001 [†]
HbA1c (%)	5.86 \pm 0.29	5.93 \pm 0.36	5.97 \pm 0.29	0.041*	6.01 \pm 0.32	6.00 \pm 0.38	6.04 \pm 0.36	0.882	0.005*
Diabetes (n, %)	7 (7.1%)	10 (10.2%)	10 (10.2%)	0.693	4 (8.9%)	4 (8.9%)	11 (25.0%)	0.043*	0.122
Prediabetes (n, %)	66 (67.3%)	73 (74.5%)	76 (77.6%)	0.255	39 (86.7%)	40 (88.9%)	32 (72.7%)	0.091	0.039*
Prediabetes plus diabetes (n, %)	73 (74.5%)	83 (84.7%)	86 (87.8%)	0.039*	43 (95.6%)	44 (97.8%)	43 (97.7%)	0.779	<0.001 [†]

* p<0.05, [†]p<0.001, § P-value for difference between MHAO and MUAO.

All percentages are column percentage; except for percentages, all values are mean \pm s.d. .

Abbreviations: 2-h PG, 2-hour plasma glucose; BMI, body mass index; HDL, high-density lipoprotein; IL1TG, intrahepatic triglyceride; LDL, low-density lipoprotein cholesterol; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OGTT, oral glucose tolerance test.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Variables	Prediabetes plus Diabetes		
	OR	95% CI	P-value
All subjects			
MUAO v.s. MHAO	10.90	3.15 - 37.69	<0.001*
NAFLD v.s. Non-NAFLD	3.02	1.47 - 6.20	0.003*
IHTG content (%) †	1.62	1.07 - 2.46	0.024*
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	1.81	0.86 - 3.81	0.117
Tertile 3	3.13	1.28 - 7.61	0.012*
Trend test			0.011*
Interaction test			
MUAO*NAFLD			0.956
MUAO*Tertiles of IHTG			0.869
MHAO subjects			
NAFLD v.s. Non-NAFLD	2.65	1.25 - 5.60	0.011*
IHTG content (%) †	1.55	1.00 - 2.40	0.051
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	2.31	1.03 - 5.17	0.042*
Tertile 3	2.81	1.14 - 6.90	0.024*
Trend test			0.021*
MUAO subjects			
NAFLD v.s. Non-NAFLD	4.77	0.07 - 327.48	0.469
IHTG content (%) †	0.81	0.13 - 5.26	0.830
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	3.22	0.24 - 43.54	0.378
Tertile 3	1.90	0.15 - 23.69	0.620
Trend test			0.558

*p<0.05

† OR and 95%CI was expressed by per SD increase of IHTG content.

‡ OR and 95%CI was expressed by the first quartile of IHTG content as the reference.


Abbreviations: CI, confidence interval; IHTG, intrahepatic triglyceride; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio;

OR was adjusted for age, sex, educational level, ever smoking, ever drinking, physical


1
2
3 activity, BMI, systolic and diastolic BP, triglyceride, total cholesterol, HDL- and LDL-
4 cholesterol and serum uric acid.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



402x251mm (47 x 47 DPI)



404x244mm (47 x 47 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	12-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-14

		(b) Report category boundaries when continuous variables were categorized	13-14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of prediabetes plus diabetes: an observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057820.R1
Article Type:	Original research
Date Submitted by the Author:	03-Dec-2021
Complete List of Authors:	Xu, Qiaoyan; The First Affiliated Hospital of Xiamen University Zhang, Junfeng ; The First Affiliated Hospital of Xiamen University Lai, Fangfang ; The First Affiliated Hospital of Xiamen University chen, ning; Xiamen branch, Zhongshan hospital, Fudan University, Xiamen, China, Endocrinology Lin, Mingzhu; Department of Endocrinology and Diabetes Liu, Yongwen; Department of Nursing Zhang, Wei ; The First Affiliated Hospital of Xiamen University Wang, Shunqin ; Children's Hospital of Fudan University Xiamen Branch & Xiamen Children's Hospital Liu, Changqin; The First Affiliated Hospital of Xiamen University, Department of Endocrinology and Diabetes li, Zhibin; The First Affiliated Hospital of Xiamen University, Epidemiology Research Unit of Translational Medicine Research Center
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Adult gastroenterology < GASTROENTEROLOGY, Hepatology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Manuscript Type: Original Article

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of prediabetes plus diabetes: an observational study

Qiaoyan Xu^{a#}, Junfeng Zhang^{a#}, Fangfang Lai^{a#}, Ning Chen^{b#}, Mingzhu Lin^c,
Yongwen Liu^d, Wei Zhang^e, Shunqin Wang^f, Changqin Liu^{c*}, Zhibin Li^{g*}

^a Lianqian Community Health Service Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

^b Department of Endocrinology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, China

^c Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China

^d Department of Nursing, The First Affiliated Hospital of Xiamen University, Xiamen, China

^e Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen, China

^f Key laboratory of Neonatal Diseases, Children's Hospital of Fudan University Xiamen Branch & Xiamen Children's Hospital, Xiamen, China

^g Epidemiology Research Unit, Translational Medicine Research Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

Running title: Association of IHTG content in MHAO with prediabetes

1
2
3
4 **Word count: 3307**

5
6 **Number of tables and figures: 5**

7
8
9 # These authors contribute to this work equally.

10
11 * Corresponding authors and persons to whom reprint requests should be addressed:

12
13
14 Dr. Changqin Liu

15
16 Department of Endocrinology and Diabetes,

17
18 The First Affiliated Hospital, Xiamen University & The Teaching Hospital of Fujian Medical

19
20
21 University

22
23
24 No.55 Zhenhai Road, Xaimen 361003, China.

25
26
27 Phone: +86-592-2137610;

28
29
30 Fax: +86-592-2137557;

31
32
33 Email: liuchangqin@xmu.edu.cn

34
35 &

36
37
38 Dr. Zhibin Li

39
40
41 Epidemiology Research Unit,

42
43
44 Translational Medicine Research Center,

45
46
47 The First Affiliated Hospital, Xiamen University

48
49
50 No.55 Zhenhai Road, Xiamen 361003, China

51
52
53 Phone: +86-592-2137364;

54
55
56 Fax: +86-592-2137557;

57
58
59 Email: zhibinli33@hotmail.com

ABSTRACT

Objective We aimed to evaluate the association of intrahepatic triglyceride (IHTG) content in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes plus diabetes.

Design Cross-sectional survey.

Setting Lianqian community, the First Affiliated Hospital of Xiamen University, Xiamen, China.

Participants Among 1,523 community-living healthy adults aged 40 years or older with abdominal obesity recruited at baseline, 428 subjects who underwent intrahepatic triglyceride (IHTG) content measurement selected at random chose to participate.

Outcome measures metabolically healthy abdominal obesity (MHAO), metabolically unhealthy abdominal obesity (MUAO), prediabetes, and diabetes.

Results Nonalcoholic fatty liver disease (NAFLD) were diagnosed as 203 (69.1%) in MHAO and 121 (90.3%) in metabolically unhealthy abdominal obesity (MUAO) ($p < 0.001$). The prevalence rates of prediabetes plus diabetes were 81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p = 0.037$). Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-NAFLD) were independently associated with increased risks of prediabetes plus diabetes, the adjusted ORs (95% CIs) were 10.90 (3.15-37.69, $p < 0.001$) and 3.02 (1.47-6.20, $p = 0.003$), respectively. Higher IHTG content was significantly associated with increased risk of prediabetes plus diabetes with the adjusted OR (95% CI) of per SD increase of IHTG content of 1.62 (1.07-2.46, $p = 0.024$). And there was a significantly positive trend between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes (trend test

1
2
3
4 p-value =0.011). Stratified analyses showed similar results on the associations of NAFLD
5
6 and IHTG content with risks of prediabetes plus diabetes for subjects with MHAO but not for
7
8 those with MUAO.
9

10
11 **Conclusions:** NAFLD and higher IHTG content were independently associated with
12
13 increased risks of prediabetes plus diabetes in MHAO subjects. NAFLD or quantity of liver
14
15 fat should be considered as additional criterion when defining and diagnosing MHO.
16
17

18
19 Screening of NAFLD and intervention to reduce liver fat should be strengthened even for the
20
21 seemingly metabolically healthy obese.
22
23

24
25 **Keywords:** metabolically healthy obesity; intrahepatic triglyceride; nonalcoholic fatty liver
26
27 disease; prediabetes; diabetes;
28
29

30 31 32 **Strengths and limitations of this study** 33

- 34
35 ➤ IHTG content was determined using magnetic resonance spectroscopy, which was
36
37 relatively quantitative measurement of liver fat.
38
- 39
40 ➤ Both NAFLD and higher IHTG content were independently associated with increased
41
42 risks of prediabetes plus diabetes in MHAO subjects.
43
- 44
45 ➤ Quantity of liver fat or NAFLD should be considered as additional criterion when
46
47 defining and diagnosing MHO, and screening of NAFLD and intervention to reduce liver
48
49 fat should be strengthened even for the seemingly metabolically healthy obese subjects.
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

The prevalence of diabetes has quadrupled during the past three decades with an estimated prevalence of 9.3% (463 million people) in 2019 and it is expected to rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [1-3]. Obesity has been well documented to be a risk factor for a broad array of chronic non-communicable diseases, including diabetes, hypertension, coronary heart disease, chronic kidney disease and certain sites of cancer [4-6]. A subgroup of obese individuals who are devoid of obesity-related metabolic complications, such as diabetes and atherosclerosis, arise the concept of metabolically healthy obese (MHO) [7-9]. However, there is no unique definition and diagnose criteria for MHO by now. For example, some defined MHO when two or fewer of the 4 criteria of metabolism syndrome [10] for those obese subjects while others defined as none of them [11], which made evidence on the association of MHO with diabetes was limited and controversial [12].

Nonalcoholic fatty liver disease (NAFLD) is well documented to be associated with risk of diabetes [13], however NAFLD has not been considered as additional criterion for MHO although it usually occurs simultaneously when obesity happens. Therefore, little evidence is available on the risk of NAFLD or liver fat with diabetes for those with MHO. In the present study with 428 community-living Chinese adults with abdominal obesity, we mainly aimed to evaluate associations of intrahepatic triglyceride (IHTG) content and NAFLD in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes plus diabetes.

METHODS

Study design and subjects

Details on study design and subjects recruitment have been described previously [14,15].

Briefly, 1,523 community-living healthy adults aged 40 years or older with abdominal

obesity (waist circumference greater than 90 cm for men and 80 cm for women) living in

Lianqian community, Xiamen, China were recruited at baseline of the cohort study in 2011.

Of them, 92 (6%) who had incomplete data on clinical and biochemistry measurements were

excluded, and a random sample of 428 subjects who underwent intrahepatic triglyceride

(IHTG) content measurement was left for the present analysis (Figure 1). Of the 428 study

subjects, 319 (74.5%) were female with the mean age of 53.6 ± 6.5 years old, 109 (25.5%)

were male with the mean age of 53.2 ± 7.1 years old, and there was no significant difference in

age between male and female subjects ($p=0.592$). This study was approved by the Human

Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen,

China) and conducted according to the principles of the Declaration of Helsinki. Written

informed consent was obtained from each participant.

Measurements

For each subject, face-to-face interview was conducted to collect socio-demographic status,

lifestyle habits, present and previous history of health and medications. Subjects were

excluded if they drank regularly with alcohol consumption ≥ 140 g/week for men or ≥ 70

g/week for women, had cancer, or received current treatment with systemic corticosteroids,

biliary obstructive diseases, acute or chronic virus hepatitis, drug-induced liver diseases, total

1
2
3
4 parenteral nutrition, autoimmune hepatitis, Wilson's disease, known hyperthyroidism or
5
6 hypothyroidism. Subjects underwent weight, height and waist circumference measurements
7
8
9 by using a calibrated scale after removing shoes and heavy clothes. Waist circumference was
10
11 measured at the midpoint between the inferior costal margin and the superior border of the
12
13 iliac crest on the midaxillary line. Body mass index (BMI) was calculated as weight in
14
15 kilograms divided by height in squared meters. Arterial blood pressure (BP) was measured
16
17 with a mercury sphygmomanometer after sitting for at least 15 minutes.
18
19
20
21
22
23

24
25 Blood samples were obtained after 12-hour fasting and 75-g oral glucose tolerance test were
26
27 conducted for each subject. All biochemical measurements were tested in the central
28
29 laboratory of the First Affiliated Hospital, Xiamen University. Plasma glucose and serum
30
31 lipid profiles, including triglyceride (TG), total cholesterol (TC), and high-density lipoprotein
32
33 cholesterol (HDL-C) were determined on a HITACHI 7450 analyzer (HITACHI, Tokyo,
34
35 Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's
36
37 formula. Fasting plasma glucose (FPG) and 2-hour plasma glucose (2-h PG) concentrations
38
39 were measured by the hexokinase method and HbA1c by the Bio-Rad Variant Hemoglobin A1c
40
41 assay.
42
43
44
45
46
47
48
49
50

51 **Ultrasonography and definition of non-alcoholic fatty liver disease**

52
53 Hepatic ultrasonography scanning was performed by an experienced radiologist using GE
54
55 LOGIQ P5 scanner (GE Healthcare, Milwaukee, USA) with a 4-MHz probe, who was
56
57 blinded to the subjects' health status. Hepatic steatosis was diagnosed on the basis of
58
59
60

1
2
3
4 characteristic sonographic features, including hepatorenal echo contrast, liver parenchymal
5
6 brightness, deep beam attenuation, and vessel blurring [16]. The definition of NAFLD was
7
8 based on hepatic ultrasonography diagnosis of hepatic steatosis without excessive alcohol
9
10 consumption, viral or autoimmune liver disease.
11
12
13
14
15
16

17 **Intrahepatic triglyceride (IHTG) content measurement**

18
19 IHTG content was determined by an experienced radiologist using Magnetic resonance
20
21 spectroscopy (^1H MRS, 3.0-T Avanto, Siemens AG, Erlangen, German). Images of a sagittal,
22
23 coronal and axial cube of a 2 cm^3 volume in the right lobe of liver was acquired.
24
25
26

27 Quantification of the spectra (water and methylene resonances) was performed as described
28
29 previously [17]. Areas of resonance from water protons and methylene groups in fatty acid
30
31 chains were obtained with a time-domain non-linear fitting routine by using Syngo MR B15V
32
33 software (Siemens AG). The percentage of IHTG content was calculated as the ratio of the
34
35 area under the resonance of peak for methylene groups in fatty acid chains of IHTG and the
36
37 combined area under the resonance peaks for both methylene groups and water.
38
39
40
41
42
43
44

45 **Definition of metabolically healthy abdominal obesity**

46
47 Abdominal obesity was defined as WC $\geq 90\text{cm}$ for men and 80cm for women [18]. All
48
49 subjects in the present study were abdominal obesity which was considered as one of the
50
51 recruitment criteria. Subjects were defined as metabolically healthy abdominal obesity
52
53 (MHAO) if two or fewer of the following criteria were met: ①systolic BP ≥ 130 or diastolic
54
55 BP ≥ 85 mmHg; ②fasting plasma glucose (FPG) ≥ 100 mg/dL (5.6 mmol/L); ③TG ≥ 150
56
57
58
59
60

1
2
3
4 mg/dL (1.7 mmol/L); ④HDL cholesterol < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL
5
6 (1.30 mmol/L) in women [19,20]. Otherwise, subjects meeting 3 or more of the criteria were
7
8 defined as metabolically unhealthy abdominal obesity (MUAO). Therefore, all subjects in the
9
10 present study were dichotomized as either MHAO or MUAO.
11
12
13
14
15
16

17 **Definitions of diabetes and prediabetes**

18
19 According to American Diabetes Association (ADA) 2020 criteria, diabetes was defined as
20
21 (1) a self-reported history of diabetes previously diagnosed by health care professionals; (2)
22
23 FGP \geq 126 mg/dL (7.0mmol/L); (3) 2-hour plasma glucose (2-h PG, OGTT) \geq 200 mg/dL
24
25 (11.1mmol/L); or (4) HbA1c \geq 6.5%. Prediabetes was defined as (1) FPG levels between 100
26
27 mg/dL (5.6mmol/L) and 125 mg/ dL (6.9mmol/L), (2) 2-h PG levels between 140 mg/dL
28
29 (7.8mmol/L) and 199 mg/dL (11.0mmol/L), or (3) HbA1c between 5.7% and 6.4% in
30
31 participants without a prior diabetes diagnosis [21].
32
33
34
35
36
37
38
39
40

41 **Statistical analyses**

42
43 Data were presented as the mean \pm standard deviation for continuous variables or number and
44
45 percentage for categorical variables. Skewness and kurtosis tests for continuous variables
46
47 were conducted and found them followed approximation of normal distributions. Differences
48
49 between subjects categorized by MHAO and tertiles of IHTG content were analyzed using
50
51 one-way ANOVA for continuous variables and chi-square test for categorical variables. Bar
52
53 graphs showing prevalence rates of diabetes, prediabetes and normal glucose test (NGT) were
54
55 made by MHAO (v.s. MUAO) and tertiles of IHTG content.
56
57
58
59
60

1
2
3
4
5
6
7 Multivariable logistic regression models were used to calculate the adjusted odds ratios (ORs)
8
9 and 95% confidence intervals (CIs) of abdominal obesity (MUAO v.s. MHAO), NAFLD (yes
10
11 v.s. no) and IHTG content (both the originally continuous values and the tertiles categories)
12
13 for prediabetes plus diabetes with adjustment for potential confounders (including age, sex,
14
15 educational level, smoking and drinking habits, regular physical exercise, BMI, systolic and
16
17 diastolic BP, triglyceride, total cholesterol, HDL- and LDL-cholesterol and serum uric acid).
18
19 And multivariable logistic regression analyses stratified by MHAO and MUAO groups were
20
21 further conducted. All p-values were two-sided and p-value <0.05 was considered statistically
22
23 significant. All statistical analyses were performed using Stata14.0 (StatCorp, College
24
25 Station, TX).
26
27
28
29
30
31
32
33
34

35 **Patient and public involvement**

36
37 There were no funds or time allocated for patient and public involvement.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Prevalence of diabetes and prediabetes stratified by MHAO and tertiles of IHTG content

Among the 428 subjects with abdominal obesity, MHAO and MUAO were identified on 294 (68.7%) and 134 (31.3%) subjects. Of them, 46 (10.8%), 326 (76.2%) and 56 (13.1%) were diagnosed as diabetes, prediabetes and normal glucose tolerance (NGT), respectively. There was a significantly positive trend between increasing tertiles of IHTG content and higher prevalence of prediabetes plus diabetes (81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p=0.037$)). Figure 2A showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MHAO subjects were 7.1% and 67.3%, 10.2% and 74.5%, 10.2% and 77.6% for the Tertile 1, Tertile 2 and Tertile 3, respectively ($p\text{-value}>0.05$). But there was a significantly positive trend of higher prevalence of diabetes plus diabetes with increasing categories of tertiles of IHTG content ($p=0.039$). Figure 2B showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MUAO subjects were 8.9% and 86.7%, 8.9% and 88.9%, 25.0% and 72.7% for Tertile 1, Tertile 2 and Tertile 3, respectively. Table 1 also showed MUAO subjects had significantly higher prevalence of prediabetes and prediabetes plus diabetes than MHAO subjects (both $p\text{-values}<0.05$).

Demographic and clinical characteristics stratified MHAO and tertiles of IHTG content

For all the 428 subjects, the means (\pm SD) of age were 53.6 (\pm 6.5) years for women ($n=319$, 74.5%) and 53.2 (\pm 7.1) years for men ($n=109$, 25.5%) ($p=0.592$). Table 1 showed differences of demographics, life style habits and clinical characteristics stratified by MHAO and tertiles

1
2
3
4 of IHTG content. For 294 MHAO subjects, with increasing categories of the tertiles of IHTG
5
6 content (from tertile 1, tertile 2 to tertile 3), subjects were more likely to be male and had
7
8 significantly higher levels of indices of obesity (BMI, waist circumference), diastolic BP,
9
10 significantly higher levels of indices of obesity (BMI, waist circumference), diastolic BP,
11
12 triglyceride, HbA1c, serum uric acid as well as higher prevalence of NAFLD and
13
14 significantly lower level of HDL-C. As for 134 MUAO subjects, increasing categories of the
15
16 tertiles of IHTG content were significantly related to higher prevalence of NAFLD and serum
17
18 uric acid levels. Furthermore, Table 1 showed that, compared to subjects with MHAO, those
19
20 with MUAO had significantly increased age, IHTG content, prevalence of NAFLD, systolic
21
22 and diastolic BP, triglyceride, total cholesterol, FPG, 2-h PG, HbA1c, serum uric acid and
23
24 significantly lower level of HDL-C.
25
26
27
28
29
30
31

32 **Associations of MHAO, NAFLD and IHTG content with prediabetes plus diabetes for** 33 **all subjects** 34 35 36

37 Table 2 showed that, for all subjects, both MUAO (v.s. MHAO) and NAFLD (yes v.s. no)
38
39 were independently associated with increased risk of prediabetes plus diabetes, and the
40
41 adjusted ORs (95% CIs) were 10.90 (3.15-37.69, $p < 0.001$) and 3.02 (1.47-6.20, $p = 0.003$),
42
43 respectively. Higher IHTG content was significantly associated with increased risk of
44
45 prediabetes plus diabetes with the adjusted OR (95% CI) of per SD increase of IHTG content
46
47 of 1.62 (1.07-2.46, $p = 0.024$). With the tertile 1 of IHTG content as the reference, the tertile 3
48
49 showed significantly higher risk of prediabetes plus diabetes (adjusted OR (95% CI): 3.13
50
51 (1.28-7.61), $p = 0.012$). And there was a significantly positive trend of increasing categories of
52
53 IHTG content tertiles with excessive risk of prediabetes plus diabetes (trend test: $p = 0.011$).
54
55
56
57
58
59
60

1
2
3
4 There was no significant interaction between MHAO with either NAFLD or tertiles of IHTG
5
6 content for risk of prediabetes plus diabetes (both p-values>0.05).
7
8
9

10 11 **Stratified analyses on associations of NAFLD and IHTG content with prediabetes plus** 12 13 **diabetes by MHAO & MUAO** 14

15
16 Multivariable logistic regression analyses stratified by MHAO and MUAO separately were
17
18 conducted. For MHAO subjects, NAFLD was independently associated with increased risk of
19
20 prediabetes plus diabetes (adjusted OR (95%CI): 2.65 (1.25-5.60), p=0.011). Per SD increase
21
22 of IHTG content was marginally associated with excessive risk of prediabetes plus diabetes
23
24 with the adjusted OR (95%CI) of 1.55 (1.00-2.40, p=0.051). Compared with the tertile 1 of
25
26 IHTG content, both the tertile 2 and tertile 3 groups showed significantly increased risks of
27
28 prediabetes plus diabetes with the adjusted ORs (95%CI) of 2.31 (1.03-5.17, p=0.042) and
29
30 2.81 (1.14-6.90, p=0.024), respectively. And there was also a significantly positive trend
31
32 between increasing categories of IHTG content tertiles and excessive risk of prediabetes plus
33
34 diabetes (trend test: p=0.021). For MUAO subjects, neither NAFLD nor IHTG content was
35
36 found to be significantly associated with risk of prediabetes plus diabetes.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

In the present study of 428 subjects with abdominal obesity, 294 (68.7%) and 134 (31.3%) were identified as MHAO and MUAO, respectively. Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-NAFLD) were independently associated with increased risks of prediabetes plus diabetes. Furthermore, higher IHTG content was significantly associated with increased risk of prediabetes plus diabetes, and there was a significantly positive trend between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes. Stratified analyses showed similar results for subjects with MHAO but not for those with MUAO.

The concept of MHO has been established for a subgroup of obese subjects who do not exhibit metabolic and cardiovascular complications at a given time point, such as diabetes and atherosclerosis, for a few decades [22,23]. Compared to subjects with MUO, those with MHO are characterized by lower liver and visceral fat, higher subcutaneous leg fat, greater cardiorespiratory fitness, physical activity and insulin sensitivity, lower levels of inflammation, and normal adipose tissue function [24]. However, it could be debated whether MHO predicts the risk of diabetes compared with metabolically healthy normal weight or MUO. Hinnouho GM et al, based on the Whitehall II cohort study, found a significantly decreased risk of diabetes for MHO compared with metabolically unhealthy obesity (MUO) (HR=1.98 (MUO v.s. MHO), 95% CI: 1.39–2.83) [25]. The present study found similar results that MUAO was significantly associated with increased risk of prediabetes plus diabetes compared with MHAO but with a much higher adjusted OR(95%CI) (10.90 (3.15-37.69)). Hinnouho GM et al and others further found that MHO showed a significant

1
2
3
4 increased risk of T2DM incidence compared with metabolically healthy normal weight [25-
5
6
7 27]. We cannot evaluate the risk of MHAO on diabetes compared with metabolically healthy
8
9 normal weight since all the subjects in the present study were central obese and none of them
10
11 could be classified as metabolically healthy or unhealthy normal weight. And because we had
12
13 a relatively small sample size, we might find the adjusted OR was much higher than those
14
15
16
17 from other [25-27].

18
19
20
21
22 Little evidence is available on differences of prevalence of NAFLD or liver fat content
23
24 between MHO and MUO. In the present study, we found subjects with MUO, compared to
25
26 those with MHO, showed significantly higher prevalence of NAFLD (90.3% v.s. 69.1%) and
27
28 IHTG content (16.3 ± 9.5 v.s. $12.3\pm 9.5\%$) (both p-values<0.001). Our findings indicated the
29
30 prevalence of NAFLD and IHTG content are still common and high even for those with
31
32 MHO. Meanwhile MHO is commonly identified based on the presence of obesity and
33
34 absence of metabolic syndrome, neither NAFLD nor liver fat content has been considered as
35
36 an additional criterion when defining and diagnosing MHO. Therefore, our findings implied
37
38 that screening of NAFLD and intervention to reduce IHTG content for those seemingly healthy
39
40 obese should be strengthened.
41
42
43
44
45
46
47
48
49

50
51 Our previous findings showed that NAFLD was significantly associated with increased risk
52
53 of T2DM prevalence [28]. The present study expanded the positive association of NAFLD to
54
55 risk of prediabetes plus diabetes for all subjects as well as for those with MHAO, and the
56
57 adjusted ORs (95%CI) were 3.02 (1.47-6.20) and 2.65 (1.25-5.60) (both p-values<0.05),
58
59
60

1
2
3
4 respectively. NAFLD has been generally diagnosed by hepatic ultrasonography scanning. In
5
6 the present study, we conducted IHTG content measurement by using magnetic resonance
7
8 spectroscopy to quantify the extent of liver fat in these abdominal obese subjects. And we
9
10 found that IHTG content was significantly associated with increased risk of prediabetes plus
11
12 diabetes with the adjusted OR (95%CI) of per SD increase of IHTG content of 1.62 (1.07-
13
14 2.46, $p=0.024$). Moreover, we found a significantly positive trend between increasing
15
16 categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes.
17
18

19
20 Quantitative MRI proton-density fat fraction method has been proved to serve as accurate
21
22 noninvasive biomarkers for quantifying liver steatosis [29] and liver fat content was found to
23
24 be correlated with insulin resistance [30], but evidence was scarce on association between the
25
26 quantity of liver fat and risk of diabetes. Our results on the association between IHTG content
27
28 and risks of prediabetes plus diabetes might account for possibly a novel finding for the
29
30 present study.
31
32
33
34
35
36
37
38
39

40 We further conducted stratified analyses on the associations of IHTG content with risk of
41
42 prediabetes plus diabetes for subjects with MHAO and MUAO separately. For those with
43
44 MHAO, the association of IHTG content with risk of prediabetes plus diabetes was
45
46 marginally significant, and the adjusted OR (95%CI) of per SD increase of IHTG content was
47
48 1.55 (1.00-2.40, $p=0.051$). With the first tertile of IHTG content as the reference group, the
49
50 adjusted ORs (95%CI) of risks of prediabetes plus diabetes for the 2nd and 3rd tertiles were
51
52 2.31 (1.03-5.17) and 2.81 (1.14-6.90) (both p -values <0.05), respectively. The positive trend
53
54 between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus
55
56
57
58
59
60

1
2
3
4 diabetes was also statistically significant for the subgroup with MHAO (trend test p-
5
6 value<0.05). Our findings implied that increased intrahepatic triglyceride content was
7
8 associated with excessive risk of prediabetes and diabetes even for MHO subjects. To the
9
10 best of our knowledge, we were probably the first to find the positive associations of IHTG
11
12 content with risks of diabetes and prediabetes for MHAO subjects. The reason for non-
13
14 significant results for MUAO subgroups may be due to the relatively small sample size of
15
16 subjects with MUAO (n=134).
17
18
19
20
21
22
23
24

25 NAFLD and liver fat quantity has not been currently considered in the definitions and
26
27 diagnose criteria of MHO [24], although liver is one of the main parts of fat accumulation
28
29 when obesity occurs. The present study found that around 69% of subjects with MHAO were
30
31 diagnosed as NAFLD. Most importantly, even for these apparently metabolically healthy
32
33 obese individuals, NAFLD and higher IHTG content were both significantly associated with
34
35 increased risks of prediabetes plus diabetes. Therefore, our findings implied that the current
36
37 criteria of MHO may not be appropriate. NAFLD, quantity of liver fat or abdominal fat
38
39 content (obtained from ultrasonography or CT-scanning techniques) should be considered as
40
41 additional criterion when defining and diagnosing MHO if more evidence could be proved in
42
43 future, especially from the prospective cohort studies with larger sample sizes.
44
45
46
47
48
49
50
51
52

53 A few limitations of the present study should be recognized when generalizing our findings to
54
55 other populations. Firstly, all subjects were abdominally obese and were not randomly
56
57 sampled from their living communities; therefore, we could not assess the effect of MHAO as
58
59
60

1
2
3
4 compared with metabolically healthy non-obesity and we might also under-estimate the true
5
6 associations of MHAO as compared with MUAO on risks of prediabetes plus diabetes.
7

8
9 Secondly, the present analyses were based on the baseline information of our ongoing cohort
10
11 study, therefore we cannot determine the temporal sequence among MHAO and prediabetes
12
13 plus diabetes. Thirdly, our sample size was small, especially for the MUAO subgroup and we
14
15 may not have enough power to determine their true associations. On the other hand, we still
16
17 have some strengths in the present study. For example, we used IHTG content by magnetic
18
19 resonance spectroscopy, which was relatively measurement of liver fat. And we were
20
21 probably the first to find the positive associations of IHTG content with risks of diabetes and
22
23 prediabetes, especially for subjects with MHAO.
24
25
26
27
28
29
30
31

32 **CONCLUSIONS**

33
34
35 NAFLD were diagnosed in 69% of MHAO and 90% of MUAO subjects, and the prevalence
36
37 rates of prediabetes plus diabetes were linearly increased across the tertiles of IHTG content.
38
39
40 NAFLD and higher IHTG content were independently associated with increased risks of
41
42 prediabetes plus diabetes for all subjects as well as for the MHAO subgroups. Therefore, our
43
44 findings imply that NAFLD or quantity of liver fat should be considered as additional
45
46 criterion when defining and diagnosing MHO. Furthermore, screening of NAFLD and
47
48 intervention to reduce liver fat should be strengthened even for the seemingly healthy obese
49
50
51 subjects.
52
53
54
55
56
57
58
59
60

Declarations

Acknowledgements

This study was completed with the assistance of the Lianqian community health service center, Xiamen, China. And we are grateful to all the subjects for their participation.

Author contributions

Q.X., J.Z., F.L., N.C. and Z.L. performed the statistical analysis and wrote the manuscript; M.L. and Y.L. participated in the data collection; S.W. and W.Z. contributed to discussion; C.L., N.C., S.W. and J.Z. participated in the design of the study and edited the manuscript.

C.L. and Z.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This study was supported by the grants from National Key R&D Program of China (No. 2017YFC0907100), Natural Science Foundation of China (No. 81870611), Open project of State Key Laboratory of Cellular Stress Biology, and Xiamen University (No. SKLCSB2019KF004).

Conflict of interest statement

No potential conflict of interest relevant to this article is declared.

Ethical approval

This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China) (number/ID of the obtained ethics approval:

1
2
3
4 2011YLS-013) and conducted according to the principles of the Declaration of Helsinki.
5

6 Written informed consent was obtained from each participant.
7
8

9 **Data availability**

10
11 The datasets generated during and/or analyzed during the current study are available from the
12
13
14 corresponding author upon reasonable request.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

- [1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* 2019;157:107843.
- [2]. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018;14(2):88-98.
- [3] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017;389(10085):2239-51.
- [4] Legler J, Fletcher T, Govarts E, et al. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. *J Clin Endocrinol Metab* 2015;100(4):1278-88.
- [5] Collaborators GBDO, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017;377(1):13-27.
- [6] Prospective Studies C, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009;373(9669):1083-96.
- [7] Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. *Am J Clin Nutr* 1956;4(1):20-34.
- [8] Sims EA. Are there persons who are obese, but metabolically healthy? *Metabolism* 2001;50(12):1499-504.
- [9] Stefan N, Haring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. *Lancet Diabetes Endocrinol* 2013;1(2):152-62.
- [10] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint

- interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120(16):1640-5.
- [11] Zhao Y, Qin P, Sun H, et al. Metabolically healthy general and abdominal obesity are associated with increased risk of hypertension. *Br J Nutr* 2020;123(5):583-91.
- [12] Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15(6):504-15.
- [13] Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. *J Clin Endocrinol Metab* 2013;98(2):483-95.
- [14] Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. *PLoS One* 2014;9(4):e94235.
- [15] Zhang HJ, Zhang XF, Ma ZM, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. *J Hepatol* 2013;59(3):557-62.
- [16] Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. *Zhonghua Gan Zang Bing Za Zhi* 2010;18(3):163-6
- [17] Frimel TN, Deivanayagam S, Bashir A, et al. Assessment of intrahepatic triglyceride content using magnetic resonance spectroscopy. *J Cardiometab Syndr* 2007;2(2):136-8.
- [18] Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C. Predictive values of body mass index and waist circumference for risk factors of certain

- 1
2
3
4 related diseases in Chinese adults--study on optimal cut-off points of body mass index and
5
6 waist circumference in Chinese adults. *Biomed Environ Sci* 2002;15(1):83-96.
7
8
- 9 [19] Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide
10
11 definition. *Lancet* 2005;366(9491):1059-62.
12
13
- 14 [20] Fingeret M, Marques-Vidal P, Vollenweider P. Incidence of type 2 diabetes,
15
16 hypertension, and dyslipidemia in metabolically healthy obese and non-obese. *Nutr*
17
18 *Metab Cardiovasc Dis* 2018;28(10):1036-44.
19
20
- 21 [21] American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical
22
23 Care in Diabetes-2020. *Diabetes Care* 2020;43(Suppl 1):S14-S31.
24
25
- 26 [22] Stefan N, Haring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit
27
28 in obesity treatment? *Lancet Diabetes Endocrinol* 2018;6(3):249-58.
29
30
- 31 [23] Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of
32
33 metabolically benign obesity in humans. *Arch Intern Med* 2008;168(15):1609-16.
34
35
- 36 [24] Blüher M. Metabolically Healthy Obesity. *Endocr Rev* 2020;41(3): 405–420
37
38
- 39 [25] Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the
40
41 risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur*
42
43 *Heart J* 2015;36(9):551-9.
44
45
- 46 [26] Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence
47
48 in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev*
49
50 2020;36(1):e3202.
51
52
- 53 [27] Gaita D, Mosteoru S. Metabolically healthy versus unhealthy obesity and risk for
54
55 diabetes mellitus and cardiovascular diseases. *Cardiovasc Endocrinol* 2017;6(1):23-26.
56
57
58
59
60

- 1
2
3
4 [28] Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2
5
6 diabetes via inducing insulin resistance: Association and path analyses. *Cytokine*
7
8
9 2018;108:145-50.
10
11 [29] Kramer H, Pickhardt PJ, Kliewer MA, et al. Accuracy of Liver Fat Quantification With
12
13 Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR
14
15 Spectroscopy. *AJR Am J Roentgenol* 2017;208(1):92-100.
16
17
18 [30] Dong Z, Luo Y, Cai H, et al. Noninvasive fat quantification of the liver and pancreas
19
20 may provide potential biomarkers of impaired glucose tolerance and type 2 diabetes.
21
22
23
24
25 *Medicine (Baltimore)* 2016;95(23):e3858.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Study subjects' selection diagram.

Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.

Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.

Table Legends

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Variables	MHAO (n=294, 68.7%)				MUAO (n=134, 31.3%)				P-value [§]
	Tertile 1	Tertile 2	Tertile 3	P-value	Tertile 1	Tertile 2	Tertile 3	P-value	
Demographics & life style									
N (%)	98 (33.3%)	98 (33.3%)	98 (33.3%)		45 (33.6%)	44 (32.8%)			
Male gender (n, %)	12 (12.4%)	27 (27.6%)	30 (30.6%)	0.005*	11 (24.4%)	12 (27.3%)		0.347	0.160
Age (years)	52.8±6.5	53.6±6.6	52.4±6.8	0.422	54.8±6.1	44.1±7.5	55.0±6.0	0.821	0.014*
Low educational attainment, (n, %)	61 (62.2%)	48 (49.0%)	51 (52.0%)	0.241	30 (66.7%)	27 (61.4%)		0.110	0.090
Ever smoking (n, %)	16 (16.3%)	25 (25.5%)	23 (23.5%)	0.262	9 (20.0%)	11 (25.0%)		0.828	0.753
Ever drinking (n, %)	8 (8.2%)	13 (13.3%)	15 (15.3%)	0.291	2 (4.4%)	4 (9.1%)		0.216	0.317
Regular physical exercise (n, %)	34 (34.7%)	42 (42.9%)	32 (32.7%)	0.292	13 (28.9%)	10 (22.7%)		0.296	0.165
Clinical characteristics									
IHTG content (%)	4.10±1.63	9.64±1.97	23.25±8.47	<0.001 [†]	6.86±2.44	14.54±2.91	27.68±6.21	<0.001 [†]	<0.001 [†]
NAFLD (n, %)	34 (34.7%)	75 (76.5%)	94 (95.9%)	<0.001 [†]	35 (77.8%)	42 (93.3%)	44 (100.0%)	<0.001 [†]	<0.001 [†]
BMI (kg/m ²)	26.2±2.5	27.2±2.5	28.3±2.7	<0.001 [†]	27.3±2.5	27.7±3.5	28.1±2.8	0.485	0.121
Waist circumference (cm)	90.7±5.1	93.5±6.1	96.0±7.1	<0.001 [†]	94.0±5.3	93.7±7.8	95.3±6.8	0.518	0.158
Systolic blood pressure (mmHg)	125.6±17.3	130.6±17.5	129.5±15.7	0.095	139.8±12.4	140.9±15.3	143.4±12.6	0.451	<0.001 [†]
Diastolic blood pressure (mmHg)	74.0±10.0	77.8±9.8	78.4±9.7	0.004*	82.7±10.7	83.7±9.4	85.2±8.3	0.482	<0.001 [†]
Triglyceride (mmol/L)	1.22±0.57	1.56±0.82	1.89±0.98	<0.001 [†]	2.53±1.26	3.32±1.90	2.84±1.52	0.062	<0.001 [†]
Total cholesterol (mmol/L)	5.80±1.03	5.81±0.95	5.95±1.05	0.487	6.18±1.43	6.13±1.27	6.02±0.94	0.823	0.024*
HDL-cholesterol (mmol/L)	1.50±0.26	1.39±0.29	1.37±0.25	0.003*	1.20±0.19	1.14±0.22	1.18±0.20	0.401	<0.001 [†]
LDL-cholesterol (mmol/L)	3.75±0.95	3.72±0.79	3.75±1.01	0.973	3.83±1.30	3.50±1.41	3.56±0.84	0.391	0.297

Blood uric acid ($\mu\text{mol/L}$)	322.9 \pm 71.5	359.8 \pm 83.6	378.2 \pm 98.1	<0.001 [†]	348.3 \pm 84.2	321.6 \pm 90.9	426.0 \pm 108.7	<0.001 [†]	0.001*
Fasting plasma glucose (mmol/L)	5.56 \pm 0.46	5.55 \pm 0.54	5.54 \pm 0.51	0.967	5.85 \pm 0.44	5.98 \pm 0.45	5.94 \pm 0.42	0.338	<0.001 [†]
2-h PG (OGTT, mmol/L)	7.42 \pm 2.52	7.51 \pm 1.86	7.87 \pm 1.88	0.285	8.04 \pm 1.91	8.09 \pm 1.72	8.87 \pm 2.13	0.082	<0.001 [†]
HbA1c (%)	5.86 \pm 0.29	5.93 \pm 0.36	5.97 \pm 0.29	0.041*	6.01 \pm 0.32	6.00 \pm 0.38	6.04 \pm 0.36	0.882	0.005*
Diabetes (n, %)	7 (7.1%)	10 (10.2%)	10 (10.2%)	0.693	4 (8.9%)	4 (8.9%)	11 (25.0%)	0.043*	0.122
Prediabetes (n, %)	66 (67.3%)	73 (74.5%)	76 (77.6%)	0.255	39 (86.7%)	40 (88.9%)	32 (72.7%)	0.091	0.039*
Prediabetes plus diabetes (n, %)	73 (74.5%)	83 (84.7%)	86 (87.8%)	0.039*	43 (95.6%)	41 (97.8%)	43 (97.7%)	0.779	<0.001 [†]

* p<0.05, [†]p<0.001, § P-value for difference between MHAO and MUAO.

All percentages are column percentage; except for percentages, all values are mean \pm s.d. .

Abbreviations: 2-h PG, 2-hour plasma glucose; BMI, body mass index; HDL, high-density lipoprotein; IL1TG, intrahepatic triglyceride; LDL, low-density lipoprotein cholesterol; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OGTT, oral glucose tolerance test.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Variables	Prediabetes plus Diabetes		
	OR	95% CI	P-value
All subjects			
MUAO v.s. MHAO	10.90	3.15 - 37.69	<0.001*
NAFLD v.s. Non-NAFLD	3.02	1.47 - 6.20	0.003*
IHTG content (%) †	1.62	1.07 - 2.46	0.024*
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	1.81	0.86 - 3.81	0.117
Tertile 3	3.13	1.28 - 7.61	0.012*
Trend test			0.011*
Interaction test			
MUAO*NAFLD			0.956
MUAO*Tertiles of IHTG			0.869
MHAO subjects			
NAFLD v.s. Non-NAFLD	2.65	1.25 - 5.60	0.011*
IHTG content (%) †	1.55	1.00 - 2.40	0.051
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	2.31	1.03 - 5.17	0.042*
Tertile 3	2.81	1.14 - 6.90	0.024*
Trend test			0.021*
MUAO subjects			
NAFLD v.s. Non-NAFLD	4.77	0.07 - 327.48	0.469
IHTG content (%) †	0.81	0.13 - 5.26	0.830
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	3.22	0.24 - 43.54	0.378
Tertile 3	1.90	0.15 - 23.69	0.620
Trend test			0.558

*p<0.05

† OR and 95%CI was expressed by per SD increase of IHTG content.

‡ OR and 95%CI was expressed by the first quartile of IHTG content as the reference.

Abbreviations: CI, confidence interval; IHTG, intrahepatic triglyceride; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio;

OR was adjusted for age, sex, educational level, ever smoking, ever drinking, physical

1
2
3 activity, BMI, systolic and diastolic BP, triglyceride, total cholesterol, HDL- and LDL-
4 cholesterol and serum uric acid.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study subjects' selection diagram.

Figure 1. Study subjects' selection diagram.

209x296mm (300 x 300 DPI)

Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.




Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.




Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.
 Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.

209x296mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	12-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-14

		(b) Report category boundaries when continuous variables were categorized	13-14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of prediabetes plus diabetes: an observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-057820.R2
Article Type:	Original research
Date Submitted by the Author:	18-Jan-2022
Complete List of Authors:	Xu, Qiaoyan; The First Affiliated Hospital of Xiamen University Zhang, Junfeng ; The First Affiliated Hospital of Xiamen University Han, Haiwei; The First Affiliated Hospital of Xiamen University, Department of Radiology chen, ning; Xiamen branch, Zhongshan hospital, Fudan University, Xiamen, China, Endocrinology Lai, Fangfang ; The First Affiliated Hospital of Xiamen University Liu, Yongwen; Department of Nursing Huang, Caoxin; The First Affiliated Hospital of Xiamen University, Xiamen Diabetes Institute Lin, Mingzhu; Department of Endocrinology and Diabetes Zhang, Wei ; The First Affiliated Hospital of Xiamen University Wang, Shunqin ; Children's Hospital of Fudan University Xiamen Branch & Xiamen Children's Hospital Liu, Changqin; The First Affiliated Hospital of Xiamen University, Department of Endocrinology and Diabetes li, Zhibin; The First Affiliated Hospital of Xiamen University, Epidemiology Research Unit of Translational Medicine Research Center
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Epidemiology
Keywords:	General diabetes < DIABETES & ENDOCRINOLOGY, Adult gastroenterology < GASTROENTEROLOGY, Hepatology < INTERNAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Title Page

Manuscript Type: Original Article

Association between intrahepatic triglyceride content in subjects with metabolically healthy abdominal obesity and risks of prediabetes plus diabetes: an observational study

Qiaoyan Xu^{a#}, Junfeng Zhang^{a#}, Haiwei Han^{b#}, Ning Chen^{c#}, Fangfang Lai^a, Yongwen Liu^d,
Caoxin Huang^e, Mingzhu Lin^f, Wei Zhang^g, Shunqin Wang^h, Changqin Liu^{f*}, Zhibin Li^{i*}

^a Lianqian Community Health Service Center, The First Affiliated Hospital of Xiamen University, Xiamen, China

^b Department of Radiology, The First Affiliated Hospital of Xiamen University, Xiamen, China

^c Department of Endocrinology, Zhongshan Hospital, Fudan University (Xiamen Branch), Xiamen, China

^d Department of Nursing, The First Affiliated Hospital of Xiamen University, Xiamen, China

^e Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, Xiamen, China

^f Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China

^g Xiamen Institute of Cardiovascular Diseases, The First Affiliated Hospital of Xiamen University, Xiamen, China

^h Key laboratory of Neonatal Diseases, Children's Hospital of Fudan University Xiamen Branch & Xiamen Children's Hospital, Xiamen, China

1
2
3
4 ¹Epidemiology Research Unit, Translational Medicine Research Center, The First Affiliated
5
6 Hospital of Xiamen University, Xiamen, China
7

8
9 ***Running title: Association of IHTG content in MHAO with prediabetes***
10

11 **Word count: 3356**
12

13
14 **Number of tables and figures: 5**
15

16
17 # These authors contribute to this work equally.
18

19 * Corresponding authors and persons to whom reprint requests should be addressed:
20

21
22 Dr. Changqin Liu
23

24 Department of Endocrinology and Diabetes,
25

26
27 The First Affiliated Hospital, Xiamen University & The Teaching Hospital of Fujian Medical
28
29 University
30

31
32 No.55 Zhenhai Road, Xaimen 361003, China.
33

34
35 Phone: +86-592-2137610;
36

37
38 Fax: +86-592-2137557;
39

40
41 Email: liuchangqin@xmu.edu.cn
42

43 &
44

45 Dr. Zhibin Li
46

47
48 Epidemiology Research Unit,
49

50
51 Translational Medicine Research Center,
52

53
54 The First Affiliated Hospital, Xiamen University
55

56
57 No.55 Zhenhai Road, Xiamen 361003, China
58

59
60 Phone: +86-592-2137364;

Fax: +86-592-2137557;

Email: zhibinli33@hotmail.com

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective We aimed to evaluate the association of intrahepatic triglyceride (IHTG) content in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes plus diabetes.

Design Cross-sectional survey.

Setting Lianqian community, the First Affiliated Hospital of Xiamen University, Xiamen, China.

Participants Among 1,523 community-living healthy adults aged 40 years or older with abdominal obesity recruited at baseline, 428 subjects who underwent intrahepatic triglyceride (IHTG) content measurement were selected.

Outcome measures Risk of prediabetes plus diabetes.

Results Nonalcoholic fatty liver disease (NAFLD) was diagnosed as 203 (69.1%) in MHAO and 121 (90.3%) in metabolically unhealthy abdominal obesity (MUAO) ($p < 0.001$). The prevalence rates of prediabetes plus diabetes were 81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p = 0.037$). Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-NAFLD) were independently associated with increased risks of prediabetes plus diabetes, the adjusted ORs (95% CIs) were 10.90 (3.15-37.69, $p < 0.001$) and 3.02 (1.47-6.20, $p = 0.003$), respectively. Higher IHTG content was significantly associated with increased risk of prediabetes plus diabetes with the adjusted OR (95% CI) of per SD increase of IHTG content of 1.62 (1.07-2.46, $p = 0.024$). And there was a significantly positive trend between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes (trend test p -value = 0.011). Stratified analyses showed similar results on the associations of NAFLD

1
2
3
4 and IHTG content with risks of prediabetes plus diabetes for subjects with MHAO but not for
5
6 those with MUAO.
7

8
9 **Conclusions:** NAFLD and higher IHTG content were independently associated with
10
11 increased risks of prediabetes plus diabetes in MHAO subjects. NAFLD or quantity of liver
12
13 fat should be considered as additional criterion when defining and diagnosing MHO.
14

15
16 Screening of NAFLD and intervention to reduce liver fat should be strengthened even for
17
18 those seemingly metabolically healthy obese.
19

20
21 **Keywords:** metabolically healthy obesity; intrahepatic triglyceride; nonalcoholic fatty liver
22
23 disease; prediabetes; diabetes;
24
25
26
27
28
29

30 **Strengths and limitations of this study**

- 31
32
33 ➤ This study was a cross-sectional analysis of baseline information on the ongoing cohort
34
35 study to evaluate the independent association of IHTG content with risk of prediabetes
36
37 plus diabetes.
38
39
40 ➤ All subjects were abdominally obese and were not randomly sampled from their living
41
42 communities.
43
44
45 ➤ IHTG content was determined using magnetic resonance spectroscopy which was
46
47 relatively quantitative measurement of liver fat.
48
49
50 ➤ The sample size was relatively small, especially for the MUAO subgroup, and we might
51
52 not have enough power to determine their true associations.
53
54
55
56
57
58
59
60

INTRODUCTION

The prevalence of diabetes has quadrupled during the past three decades with an estimated prevalence of 9.3% (463 million people) in 2019 and it is expected to rise to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045 [1-3]. Obesity has been well documented to be a risk factor for a broad array of chronic non-communicable diseases, including diabetes, hypertension, coronary heart disease, chronic kidney disease and certain sites of cancer [4-6]. A subgroup of obese individuals who are devoid of obesity-related metabolic complications, such as diabetes and atherosclerosis, arise the concept of metabolically healthy obese (MHO) [7-9]. However, there is no unique definition and diagnose criteria for MHO by now. For example, some defined MHO when two or fewer of the 4 criteria of metabolism syndrome [10] for those obese subjects while others defined as none of them [11], which made evidence on the association of MHO with diabetes was limited and controversial [12].

Nonalcoholic fatty liver disease (NAFLD) is well documented to be associated with risk of diabetes [13], however NAFLD has not been considered as additional criterion for MHO although it usually occurs simultaneously when obesity happens. Therefore, little evidence is available on the risk of NAFLD or liver fat with diabetes for those with MHO. In the present study with 428 community-living Chinese adults with abdominal obesity, we mainly aimed to evaluate associations of intrahepatic triglyceride (IHTG) content and NAFLD in subjects with metabolically healthy abdominal obesity (MHAO) on risks of prediabetes plus diabetes.

METHODS

Study design and subjects

Details on study design and subject recruitment have been described previously [14-16].

Briefly, 1,523 community-living healthy adults aged 40 years or older with abdominal obesity (waist circumference greater than 90 cm for men and 80 cm for women) living in Lianqian community, Xiamen, China were recruited at baseline of the cohort study in 2011. Of them, 92 (6%) who had incomplete data on clinical and biochemistry measurements were excluded, and a random sample of 428 subjects who underwent intrahepatic triglyceride (IHTG) content measurement was left for the present analysis (Figure 1). Of the 428 study subjects, 319 (74.5%) were female with the mean age of 53.6 ± 6.5 years old, 109 (25.5%) were male with the mean age of 53.2 ± 7.1 years old, and there was no significant difference in age between male and female subjects ($p=0.592$). This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China) and conducted according to the principles of the Declaration of Helsinki. Written informed consent was obtained from each participant.

Measurements

Details on study measurements have been described previously [15,16]. For each subject, face-to-face interview was conducted to collect socio-demographic status, lifestyle habits, present and previous history of health and medications. Subjects were excluded if they drank regularly with alcohol consumption ≥ 140 g/week for men or ≥ 70 g/week for women, had cancer, or received current treatment with systemic corticosteroids, biliary obstructive

1
2
3
4 diseases, acute or chronic virus hepatitis, drug-induced liver diseases, total parenteral
5
6 nutrition, autoimmune hepatitis, Wilson's disease, known hyperthyroidism or
7
8 hypothyroidism. Subjects underwent weight, height and waist circumference measurements
9
10 by using a calibrated scale after removing shoes and heavy clothes. Waist circumference was
11
12 measured at the midpoint between the inferior costal margin and the superior border of the
13
14 iliac crest on the midaxillary line. Body mass index (BMI) was calculated as weight in
15
16 kilograms divided by height in squared meters. Arterial blood pressure (BP) was measured
17
18 with a mercury sphygmomanometer after sitting for at least 15 minutes.
19
20
21
22
23
24
25
26

27 Blood samples were obtained after 12-hour fasting and 75-g oral glucose tolerance test were
28
29 conducted for each subject. All biochemical measurements were tested in the central
30
31 laboratory of the First Affiliated Hospital, Xiamen University. Plasma glucose and serum
32
33 lipid profiles, including triglyceride (TG), total cholesterol (TC), and high-density lipoprotein
34
35 cholesterol (HDL-C) were determined on a HITACHI 7450 analyzer (HITACHI, Tokyo,
36
37 Japan). Low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's
38
39 formula. Fasting plasma glucose (FPG) and 2-hour plasma glucose (2-h PG) concentrations
40
41 were measured by the hexokinase method and HbA1c by the Bio-Rad Variant Hemoglobin A1c
42
43 assay.
44
45
46
47
48
49
50
51
52

53 **Ultrasonography and definition of non-alcoholic fatty liver disease**

54
55 Details on ultrasonography and definition of NAFLD have been described previously [15,16].

56
57
58 Hepatic ultrasonography scanning was performed by an experienced radiologist using GE
59
60

LOGIQ P5 scanner (GE Healthcare, Milwaukee, USA) with a 4-MHz probe, who was blinded to the subjects' health status. Hepatic steatosis was diagnosed on the basis of characteristic sonographic features, including hepatorenal echo contrast, liver parenchymal brightness, deep beam attenuation, and vessel blurring [17]. The definition of NAFLD was based on hepatic ultrasonography diagnosis of hepatic steatosis without excessive alcohol consumption, viral or autoimmune liver disease [15,16].

Intrahepatic triglyceride (IHTG) content measurement

Details on intrahepatic triglyceride (IHTG) content measurement has been described previously [18]. IHTG content was determined by an experienced radiologist using Magnetic resonance spectroscopy (¹H MRS, 3.0-T Avanto, Siemens AG, Erlangen, German). Images of a sagittal, coronal and axial cube of a 2 cm³ volume in the right lobe of liver was acquired. Quantification of the spectra (water and methylene resonances) was performed as described previously [19]. Areas of resonance from water protons and methylene groups in fatty acid chains were obtained with a time-domain non-linear fitting routine by using Syngo MR B15V software (Siemens AG). The percentage of IHTG content was calculated as the ratio of the area under the resonance of peak for methylene groups in fatty acid chains of IHTG and the combined area under the resonance peaks for both methylene groups and water [18,19].

Definition of metabolically healthy abdominal obesity

Abdominal obesity was defined as WC \geq 90cm for men and 80cm for women [20]. All subjects in the present study were abdominal obesity which was considered as one of the

1
2
3
4 recruitment criteria. Subjects were defined as metabolically healthy abdominal obesity
5
6 (MHAO) if two or fewer of the following criteria were met: ①systolic BP \geq 130 or diastolic
7
8 BP \geq 85 mmHg; ②fasting plasma glucose (FPG) \geq 100 mg/dL (5.6 mmol/L); ③TG \geq 150
9
10 mg/dL (1.7 mmol/L); ④HDL cholesterol $<$ 40 mg/dL (1.03 mmol/L) in men and $<$ 50 mg/dL
11
12 (1.30 mmol/L) in women [16,21,22]. Otherwise, subjects meeting 3 or more of the criteria
13
14 were defined as metabolically unhealthy abdominal obesity (MUAO). Therefore, all subjects
15
16 in the present study were dichotomized as either MHAO or MUAO.
17
18
19
20
21
22
23
24

25 **Definitions of diabetes and prediabetes**

26
27 According to American Diabetes Association (ADA) 2020 criteria, diabetes was defined as
28
29 (1) a self-reported history of diabetes previously diagnosed by health care professionals; (2)
30
31 FPG \geq 126 mg/dL (7.0mmol/L); (3) 2-hour plasma glucose (2-h PG, OGTT) \geq 200 mg/dL
32
33 (11.1mmol/L); or (4) HbA1c \geq 6.5%. Prediabetes was defined as (1) FPG levels between 100
34
35 mg/dL (5.6mmol/L) and 125 mg/ dL (6.9mmol/L), (2) 2-h PG levels between 140 mg/dL
36
37 (7.8mmol/L) and 199 mg/dL (11.0mmol/L), or (3) HbA1c between 5.7% and 6.4% in
38
39 participants without a prior diabetes diagnosis [15,16,23].
40
41
42
43
44
45
46
47

48 **Statistical analyses**

49
50 Methods on statistical analyses were similar to our previous publications [15,16,18]. Data
51
52 were presented as the mean \pm standard deviation for continuous variables or number and
53
54 percentage for categorical variables. Skewness and kurtosis tests for continuous variables
55
56 were conducted and found them followed approximation of normal distributions. Differences
57
58
59
60

1
2
3
4 between subjects categorized by MHAO and tertiles of IHTG content were analyzed using
5
6 one-way ANOVA for continuous variables and chi-square test for categorical variables. Bar
7
8 graphs showing prevalence rates of diabetes, prediabetes and normal glucose test (NGT) were
9
10 made by MHAO (v.s. MUAO) and tertiles of IHTG content.
11
12
13
14
15
16

17 Multivariable logistic regression models were used to calculate the adjusted odds ratios (ORs)
18
19 and 95% confidence intervals (CIs) of abdominal obesity (MUAO v.s. MHAO), NAFLD (yes
20
21 v.s. no) and IHTG content (both the originally continuous values and the tertiles categories)
22
23 for prediabetes plus diabetes with adjustment for potential confounders (including age, sex,
24
25 educational level, smoking and drinking habits, regular physical exercise, BMI, systolic and
26
27 diastolic BP, triglyceride, total cholesterol, HDL- and LDL-cholesterol and serum uric acid).
28
29
30 And multivariable logistic regression analyses stratified by MHAO and MUAO groups were
31
32 further conducted. All p-values were two-sided and p-value <0.05 was considered statistically
33
34 significant. All statistical analyses were performed using Stata14.0 (StatCorp, College
35
36 Station, TX).
37
38
39
40
41
42
43
44
45

46 **Patient and public involvement**

47
48 There were no funds or time allocated for patient and public involvement.
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

Prevalence of diabetes and prediabetes stratified by MHAO and tertiles of IHTG content

Among the 428 subjects with abdominal obesity, MHAO and MUAO were identified on 294 (68.7%) and 134 (31.3%) subjects. Of them, 46 (10.8%), 326 (76.2%) and 56 (13.1%) were diagnosed as diabetes, prediabetes and normal glucose tolerance (NGT), respectively. There was a significantly positive trend between increasing tertiles of IHTG content and higher prevalence of prediabetes plus diabetes (81.1%, 88.8% and 90.9% across the tertiles of IHTG content ($p=0.037$)). Figure 2A showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MHAO subjects were 7.1% and 67.3%, 10.2% and 74.5%, 10.2% and 77.6% for the Tertile 1, Tertile 2 and Tertile 3, respectively ($p\text{-value}>0.05$). But there was a significantly positive trend of higher prevalence of diabetes plus diabetes with increasing categories of tertiles of IHTG content ($p=0.039$). Figure 2B showed the prevalence rates of diabetes and prediabetes across the tertiles of IHTG content in MUAO subjects were 8.9% and 86.7%, 8.9% and 88.9%, 25.0% and 72.7% for Tertile 1, Tertile 2 and Tertile 3, respectively. Table 1 also showed MUAO subjects had significantly higher prevalence of prediabetes and prediabetes plus diabetes than MHAO subjects (both $p\text{-values}<0.05$).

Demographic and clinical characteristics stratified by MHAO and tertiles of IHTG content

For all the 428 subjects, the means (\pm SD) of age were 53.6 (\pm 6.5) years for women ($n=319$, 74.5%) and 53.2 (\pm 7.1) years for men ($n=109$, 25.5%) ($p=0.592$). Table 1 showed differences

1
2
3
4 of demographics, life style habits and clinical characteristics stratified by MHAO and tertiles
5
6 of IHTG content. For 294 MHAO subjects, with increasing categories of the tertiles of IHTG
7
8 content (from tertile 1, tertile 2 to tertile 3), subjects were more likely to be male and had
9
10 significantly higher levels of indices of obesity (BMI, waist circumference), diastolic BP,
11
12 triglyceride, HbA1c, serum uric acid as well as higher prevalence of NAFLD and
13
14 significantly lower level of HDL-C. As for 134 MUAO subjects, increasing categories of the
15
16 tertiles of IHTG content were significantly related to higher prevalence of NAFLD and serum
17
18 uric acid levels. Furthermore, Table 1 showed that, compared to subjects with MHAO, those
19
20 with MUAO had significantly increased age, IHTG content, prevalence of NAFLD, systolic
21
22 and diastolic BP, triglyceride, total cholesterol, FPG, 2-h PG, HbA1c, serum uric acid and
23
24 significantly lower level of HDL-C.
25
26
27
28
29
30
31
32
33
34

35 **Associations of MHAO, NAFLD and IHTG content with prediabetes plus diabetes for** 36 37 **all subjects**

38
39
40 Table 2 showed that, for all subjects, both MUAO (v.s. MHAO) and NAFLD (yes v.s. no)
41
42 were independently associated with increased risk of prediabetes plus diabetes, and the
43
44 adjusted ORs (95%CI) were 10.90 (3.15-37.69, $p < 0.001$) and 3.02 (1.47-6.20, $p = 0.003$),
45
46 respectively. Higher IHTG content was significantly associated with increased risk of
47
48 prediabetes plus diabetes with the adjusted OR (95%CI) of per SD increase of IHTG content
49
50 of 1.62 (1.07-2.46, $p = 0.024$). With the tertile 1 of IHTG content as the reference, the tertile 3
51
52 showed significantly higher risk of prediabetes plus diabetes (adjusted OR (95%CI): 3.13
53
54 (1.28-7.61), $p = 0.012$). And there was a significantly positive trend of increasing categories of
55
56
57
58
59
60

IHTG content tertiles with excessive risk of prediabetes plus diabetes (trend test: $p=0.011$).

There was no significant interaction between MHAO with either NAFLD or tertiles of IHTG content for risk of prediabetes plus diabetes (both p -values >0.05).

Stratified analyses on associations of NAFLD and IHTG content with prediabetes plus diabetes by MHAO & MUAO

Multivariable logistic regression analyses stratified by MHAO and MUAO separately were conducted (Table 2). For MHAO subjects, NAFLD was independently associated with increased risk of prediabetes plus diabetes (adjusted OR (95%CI): 2.65 (1.25-5.60), $p=0.011$).

Per SD increase of IHTG content was marginally associated with excessive risk of prediabetes plus diabetes with the adjusted OR (95%CI) of 1.55 (1.00-2.40, $p=0.051$).

Compared with the tertile 1 of IHTG content, both the tertile 2 and tertile 3 groups showed significantly increased risks of prediabetes plus diabetes with the adjusted ORs (95%CI) of 2.31 (1.03-5.17, $p=0.042$) and 2.81 (1.14-6.90, $p=0.024$), respectively. And there was also a significantly positive trend between increasing categories of IHTG content tertiles and excessive risk of prediabetes plus diabetes (trend test: $p=0.021$). For MUAO subjects, neither NAFLD nor IHTG content was found to be significantly associated with risk of prediabetes plus diabetes.

DISCUSSION

In the present study of 428 subjects with abdominal obesity, 294 (68.7%) and 134 (31.3%) were identified as MHAO and MUAO, respectively. Both MUAO (v.s. MHAO) and NAFLD (v.s. Non-NAFLD) were independently associated with increased risks of prediabetes plus diabetes. Furthermore, higher IHTG content was significantly associated with increased risk of prediabetes plus diabetes, and there was a significantly positive trend between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes. Stratified analyses showed similar results for subjects with MHAO but not for those with MUAO.

The concept of MHO has been established for a subgroup of obese subjects who do not exhibit metabolic and cardiovascular complications at a given time point, such as diabetes and atherosclerosis, for a few decades [24,25]. Compared to subjects with MUO, those with MHO are characterized by lower liver and visceral fat, higher subcutaneous leg fat, greater cardiorespiratory fitness, physical activity and insulin sensitivity, lower levels of inflammation, and normal adipose tissue function [26]. However, it could be debated whether MHO predicts the risk of diabetes compared with metabolically healthy normal weight or MUO. Hinnouho GM et al, based on the Whitehall II cohort study, found a significantly decreased risk of diabetes for MHO compared with metabolically unhealthy obesity (MUO) (HR=1.98 (MUO v.s. MHO), 95% CI: 1.39–2.83) [27]. The present study found similar results that MUAO was significantly associated with increased risk of prediabetes plus diabetes compared with MHAO but with a much higher adjusted OR(95%CI) (10.90 (3.15-37.69)). Hinnouho GM et al and others further found that MHO showed a significant

1
2
3
4 increased risk of T2DM incidence compared with metabolically healthy normal weight [27-
5
6
7 29]. We cannot evaluate the risk of MHAO on diabetes compared with metabolically healthy
8
9 normal weight since all the subjects in the present study were central obese and none of them
10
11 could be classified as metabolically healthy or unhealthy normal weight. And because we had
12
13 a relatively small sample size, we might find the adjusted OR was much higher than those
14
15
16
17 from other [27-29].

18
19
20
21
22 Little evidence is available on differences of prevalence of NAFLD or liver fat content
23
24 between MHO and MUO. In the present study, we found subjects with MUO, compared to
25
26 those with MHO, showed significantly higher prevalence of NAFLD (90.3% v.s. 69.1%) and
27
28 IHTG content (16.3±9.5 v.s. 12.3±9.5%) (both p-values<0.001). Our findings indicated the
29
30 prevalence of NAFLD and IHTG content are still common and high even for those with
31
32 MHO. Meanwhile MHO is commonly identified based on the presence of obesity and
33
34 absence of metabolic syndrome, neither NAFLD nor liver fat content has been considered as
35
36 an additional criterion when defining and diagnosing MHO. Therefore, our findings implied
37
38 that screening of NAFLD and intervention to reduce IHTG content for those seemingly healthy
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
obese should be strengthened.

Our previous findings showed that NAFLD was significantly associated with increased risk
of T2DM prevalence [15]. The present study expanded the positive association of NAFLD to
risk of prediabetes plus diabetes for all subjects as well as for those with MHAO, and the
adjusted ORs (95%CI) were 3.02 (1.47-6.20) and 2.65 (1.25-5.60) (both p-values<0.05),

1
2
3
4 respectively. NAFLD has been generally diagnosed by hepatic ultrasonography scanning. In
5
6 the present study, we conducted IHTG content measurement by using magnetic resonance
7
8 spectroscopy to quantify the extent of liver fat in these abdominal obese subjects. And we
9
10 found that IHTG content was significantly associated with increased risk of prediabetes plus
11
12 diabetes with the adjusted OR (95%CI) of per SD increase of IHTG content of 1.62 (1.07-
13
14 2.46, $p=0.024$). Moreover, we found a significantly positive trend between increasing
15
16 categories of IHTG content tertiles and excessive risks of prediabetes plus diabetes.
17
18

19
20 Quantitative MRI proton-density fat fraction method has been proved to serve as accurate
21
22 noninvasive biomarkers for quantifying liver steatosis [30] and liver fat content was found to
23
24 be correlated with insulin resistance [31], but evidence was scarce on association between the
25
26 quantity of liver fat and risk of diabetes. Our results on the association between IHTG content
27
28 and risks of prediabetes plus diabetes might account for possibly a novel finding for the
29
30 present study.
31
32
33
34
35
36
37
38
39

40 We further conducted stratified analyses on the associations of IHTG content with risk of
41
42 prediabetes plus diabetes for subjects with MHAO and MUAO separately. For those with
43
44 MHAO, the association of IHTG content with risk of prediabetes plus diabetes was
45
46 marginally significant, and the adjusted OR (95%CI) of per SD increase of IHTG content was
47
48 1.55 (1.00-2.40, $p=0.051$). With the first tertile of IHTG content as the reference group, the
49
50 adjusted ORs (95%CI) of risks of prediabetes plus diabetes for the 2nd and 3rd tertiles were
51
52 2.31 (1.03-5.17) and 2.81 (1.14-6.90) (both p -values <0.05), respectively. The positive trend
53
54
55
56
57
58
59 between increasing categories of IHTG content tertiles and excessive risks of prediabetes plus
60

1
2
3
4 diabetes was also statistically significant for the subgroup with MHAO (trend test p-
5
6 value<0.05). Our findings implied that increased intrahepatic triglyceride content was
7
8 associated with excessive risk of prediabetes and diabetes even for MHO subjects. To the
9
10 best of our knowledge, we were probably the first to find the positive associations of IHTG
11
12 content with risks of diabetes and prediabetes for MHAO subjects. The reason for non-
13
14 significant results for MUAO subgroups may be due to the relatively small sample size of
15
16 subjects with MUAO (n=134).
17
18
19
20
21
22
23
24

25 NAFLD and liver fat quantity has not been currently considered in the definitions and
26
27 diagnose criteria of MHO [16,26], although liver is one of the main parts of fat accumulation
28
29 when obesity occurs. The present study found that around 69% of subjects with MHAO were
30
31 diagnosed as NAFLD. Most importantly, even for these apparently metabolically healthy
32
33 obese individuals, NAFLD and higher IHTG content were both significantly associated with
34
35 increased risks of prediabetes plus diabetes. Therefore, our findings implied that the current
36
37 criteria of MHO may not be appropriate. NAFLD, quantity of liver fat or abdominal fat
38
39 content (obtained from ultrasonography or CT-scanning techniques) should be considered as
40
41 additional criterion when defining and diagnosing MHO if more evidence could be proved in
42
43 future, especially from the prospective cohort studies with larger sample sizes.
44
45
46
47
48
49
50
51
52

53 A few limitations of the present study should be recognized when generalizing our findings to
54
55 other populations. Firstly, all subjects were abdominally obese and were not randomly
56
57 sampled from their living communities; therefore, we could not assess the effect of MHAO as
58
59
60

1
2
3
4 compared with metabolically healthy non-obesity and we might also under-estimate the true
5
6 associations of MHAO as compared with MUAO on risks of prediabetes plus diabetes.
7

8
9 Secondly, the present analyses were based on the baseline information of our ongoing cohort
10
11 study, therefore we cannot determine the temporal sequence among MHAO and prediabetes
12
13 plus diabetes. Thirdly, our sample size was small, especially for the MUAO subgroup and we
14
15 may not have enough power to determine their true associations. On the other hand, we still
16
17 have some strengths in the present study. For example, we used IHTG content by magnetic
18
19 resonance spectroscopy, which was relatively measurement of liver fat. And we were
20
21 probably the first to find the positive associations of IHTG content with risks of diabetes and
22
23 prediabetes, especially for subjects with MHAO.
24
25
26
27
28
29
30
31

32 **CONCLUSIONS**

33
34
35 NAFLD were diagnosed in 69% of MHAO and 90% of MUAO subjects, and the prevalence
36
37 rates of prediabetes plus diabetes were linearly increased across the tertiles of IHTG content.
38
39
40 NAFLD and higher IHTG content were independently associated with increased risks of
41
42 prediabetes plus diabetes for all subjects as well as for the MHAO subgroups. Therefore, our
43
44 findings imply that NAFLD or quantity of liver fat should be considered as additional
45
46 criterion when defining and diagnosing MHO. Furthermore, screening of NAFLD and
47
48 intervention to reduce liver fat should be strengthened even for the seemingly healthy obese
49
50
51 subjects.
52
53
54
55
56
57
58
59
60

Declarations

Acknowledgements

This study was completed with the assistance of the Lianqian community health service center, Xiamen, China. And we are grateful to all the subjects for their participation.

Author contributions

Q.X., J.Z., H.H., N.C. and Z.L. performed the statistical analysis and wrote the manuscript; H.H., F.L., Y.L., M.L. and C.H. participated in the data collection; S.W. and W.Z. contributed to discussion; C.L., N.C., S.W. and J.Z. participated in the design of the study and edited the manuscript. C.L. and Z.L. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding

This study was supported by the grants from National Key R&D Program of China (No. 2017YFC0907100), Natural Science Foundation of China (No. 81870611), Natural Science Foundation of Fujian Province (2019J01569), Open project of State Key Laboratory of Cellular Stress Biology, and Xiamen University (No. SKLCSB2019KF004).

Conflict of interest statement

No potential conflict of interest relevant to this article is declared.

Ethical approval

This study was approved by the Human Research Ethics Committee of the First Affiliated Hospital of Xiamen University (Xiamen, China) (number/ID of the obtained ethics approval:

1
2
3
4 2011YLS-013) and conducted according to the principles of the Declaration of Helsinki.
5

6
7 Written informed consent was obtained from each participant.
8

9 **Data availability**

10
11 The datasets generated during and/or analyzed during the current study are available from the
12
13
14 corresponding author upon reasonable request.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Reference

- [1] Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* 2019;157:107843.
- [2]. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol* 2018;14(2):88-98.
- [3] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet* 2017;389(10085):2239-51.
- [4] Legler J, Fletcher T, Govarts E, et al. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union. *J Clin Endocrinol Metab* 2015;100(4):1278-88.
- [5] Collaborators GBDO, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *N Engl J Med* 2017;377(1):13-27.
- [6] Prospective Studies C, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet* 2009;373(9669):1083-96.
- [7] Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. *Am J Clin Nutr* 1956;4(1):20-34.
- [8] Sims EA. Are there persons who are obese, but metabolically healthy? *Metabolism* 2001;50(12):1499-504.
- [9] Stefan N, Haring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. *Lancet Diabetes Endocrinol* 2013;1(2):152-62.
- [10] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint

- interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120(16):1640-5.
- [11] Zhao Y, Qin P, Sun H, et al. Metabolically healthy general and abdominal obesity are associated with increased risk of hypertension. *Br J Nutr* 2020;123(5):583-91.
- [12] Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. *Obes Rev* 2014;15(6):504-15.
- [13] Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. *J Clin Endocrinol Metab* 2013;98(2):483-95.
- [14] Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. *PLoS One* 2014;9(4):e94235.
- [15] Li Z, Lin M, Liu C, et al. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. *Cytokine*. 2018;108:145-150.
- [16] Zhang J, Xu Q, Lai F, et al. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. *BMJ Open Diabetes Research and Care* 2021;9:e002362.
- [17] Jian-gao F, Chinese Liver Disease A. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. *Zhonghua Gan Zang Bing Za Zhi* 2010;18(3):163-6

- 1
2
3
4 [18] Wang D, Liu Y, Liu S, et al. Serum fetuin-B is positively associated with intrahepatic
5 triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A
6 cross-sectional study. *J Diabetes*. 2018;10(7):581-588.
7
8
9
10
11 [19] Frimel TN, Deivanayagam S, Bashir A, et al. Assessment of intrahepatic triglyceride
12 content using magnetic resonance spectroscopy. *J Cardiometab Syndr* 2007;2(2):136-8.
13
14
15 [20] Zhou BF, Cooperative Meta-Analysis Group of the Working Group on Obesity in C.
16 Predictive values of body mass index and waist circumference for risk factors of certain
17 related diseases in Chinese adults--study on optimal cut-off points of body mass index and
18 waist circumference in Chinese adults. *Biomed Environ Sci* 2002;15(1):83-96.
19
20
21
22
23
24
25 [21] Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide
26 definition. *Lancet* 2005;366(9491):1059-62.
27
28
29
30
31
32 [22] Fingeret M, Marques-Vidal P, Vollenweider P. Incidence of type 2 diabetes,
33 hypertension, and dyslipidemia in metabolically healthy obese and non-obese. *Nutr*
34 *Metab Cardiovasc Dis* 2018;28(10):1036-44.
35
36
37
38
39
40 [23] American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical
41 Care in Diabetes-2020. *Diabetes Care* 2020;43(Suppl 1):S14-S31.
42
43
44
45 [24] Stefan N, Haring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit
46 in obesity treatment? *Lancet Diabetes Endocrinol* 2018;6(3):249-58.
47
48
49
50 [25] Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of
51 metabolically benign obesity in humans. *Arch Intern Med* 2008;168(15):1609-16.
52
53
54
55 [26] Blüher M. Metabolically Healthy Obesity. *Endocr Rev* 2020;41(3): 405–420
56
57
58
59
60

- 1
2
3 [27] Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the
4 risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *Eur*
5 *Heart J* 2015;36(9):551-9.
6
7
8
9
10 [28] Wei Y, Wang J, Han X, et al. Metabolically healthy obesity increased diabetes incidence
11 in a middle-aged and elderly Chinese population. *Diabetes Metab Res Rev*
12 2020;36(1):e3202.
13
14
15
16
17 [29] Gaita D, Mosteoru S. Metabolically healthy versus unhealthy obesity and risk for
18 diabetes mellitus and cardiovascular diseases. *Cardiovasc Endocrinol* 2017;6(1):23-26.
19
20
21
22 [30] Kramer H, Pickhardt PJ, Kliever MA, et al. Accuracy of Liver Fat Quantification With
23 Advanced CT, MRI, and Ultrasound Techniques: Prospective Comparison With MR
24 Spectroscopy. *AJR Am J Roentgenol* 2017;208(1):92-100.
25
26
27
28
29 [31] Dong Z, Luo Y, Cai H, et al. Noninvasive fat quantification of the liver and pancreas
30 may provide potential biomarkers of impaired glucose tolerance and type 2 diabetes.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Study subjects' selection diagram.

Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.

Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.

Table Legends

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Table 1. Demographic, lifestyle and clinical characteristics of 428 subjects stratified by MHAO and tertiles of IHTG content.

Variables	MHAO (n=294, 68.7%)				MUAO (n=134, 31.3%)				P-value [§]
	Tertile 1	Tertile 2	Tertile 3	P-value	Tertile 1	Tertile 2	Tertile 3	P-value	
Demographics & life style									
N (%)	98 (33.3%)	98 (33.3%)	98 (33.3%)		45 (33.6%)	44 (32.8%)			
Male gender (n, %)	12 (12.4%)	27 (27.6%)	30 (30.6%)	0.005*	11 (24.4%)	12 (27.3%)		0.347	0.160
Age (years)	52.8±6.5	53.6±6.6	52.4±6.8	0.422	54.8±6.1	44.1±7.5	55.0±6.0	0.821	0.014*
Low educational attainment, (n, %)	61 (62.2%)	48 (49.0%)	51 (52.0%)	0.241	30 (66.7%)	27 (61.4%)		0.110	0.090
Ever smoking (n, %)	16 (16.3%)	25 (25.5%)	23 (23.5%)	0.262	9 (20.0%)	11 (25.0%)		0.828	0.753
Ever drinking (n, %)	8 (8.2%)	13 (13.3%)	15 (15.3%)	0.291	2 (4.4%)	4 (9.1%)		0.216	0.317
Regular physical exercise (n, %)	34 (34.7%)	42 (42.9%)	32 (32.7%)	0.292	13 (28.9%)	10 (22.7%)		0.296	0.165
Clinical characteristics									
IHTG content (%)	4.10±1.63	9.64±1.97	23.25±8.47	<0.001 [†]	6.86±2.44	14.54±2.91	27.68±6.21	<0.001 [†]	<0.001 [†]
NAFLD (n, %)	34 (34.7%)	75 (76.5%)	94 (95.9%)	<0.001 [†]	35 (77.8%)	42 (93.3%)	44 (100.0%)	<0.001 [†]	<0.001 [†]
BMI (kg/m ²)	26.2±2.5	27.2±2.5	28.3±2.7	<0.001 [†]	27.3±2.5	27.7±3.5	28.1±2.8	0.485	0.121
Waist circumference (cm)	90.7±5.1	93.5±6.1	96.0±7.1	<0.001 [†]	94.0±5.3	93.7±7.8	95.3±6.8	0.518	0.158
Systolic blood pressure (mmHg)	125.6±17.3	130.6±17.5	129.5±15.7	0.095	139.8±12.4	140.9±15.3	143.4±12.6	0.451	<0.001 [†]
Diastolic blood pressure (mmHg)	74.0±10.0	77.8±9.8	78.4±9.7	0.004*	82.7±10.7	83.7±9.4	85.2±8.3	0.482	<0.001 [†]
Triglyceride (mmol/L)	1.22±0.57	1.56±0.82	1.89±0.98	<0.001 [†]	2.53±1.26	3.32±1.90	2.84±1.52	0.062	<0.001 [†]
Total cholesterol (mmol/L)	5.80±1.03	5.81±0.95	5.95±1.05	0.487	6.18±1.43	6.13±1.27	6.02±0.94	0.823	0.024*
HDL-cholesterol (mmol/L)	1.50±0.26	1.39±0.29	1.37±0.25	0.003*	1.20±0.19	1.14±0.22	1.18±0.20	0.401	<0.001 [†]
LDL-cholesterol (mmol/L)	3.75±0.95	3.72±0.79	3.75±1.01	0.973	3.83±1.30	3.50±1.41	3.56±0.84	0.391	0.297

Blood uric acid ($\mu\text{mol/L}$)	322.9 \pm 71.5	359.8 \pm 83.6	378.2 \pm 98.1	<0.001 [†]	348.3 \pm 84.2	321.6 \pm 90.9	426.0 \pm 108.7	<0.001 [†]	0.001*
Fasting plasma glucose (mmol/L)	5.56 \pm 0.46	5.55 \pm 0.54	5.54 \pm 0.51	0.967	5.85 \pm 0.44	5.98 \pm 0.45	5.94 \pm 0.42	0.338	<0.001 [†]
2-h PG (OGTT, mmol/L)	7.42 \pm 2.52	7.51 \pm 1.86	7.87 \pm 1.88	0.285	8.04 \pm 1.91	8.09 \pm 1.72	8.87 \pm 2.13	0.082	<0.001 [†]
HbA1c (%)	5.86 \pm 0.29	5.93 \pm 0.36	5.97 \pm 0.29	0.041*	6.01 \pm 0.32	6.00 \pm 0.38	6.04 \pm 0.36	0.882	0.005*
Diabetes (n, %)	7 (7.1%)	10 (10.2%)	10 (10.2%)	0.693	4 (8.9%)	4 (8.9%)	11 (25.0%)	0.043*	0.122
Prediabetes (n, %)	66 (67.3%)	73 (74.5%)	76 (77.6%)	0.255	39 (86.7%)	40 (88.9%)	32 (72.7%)	0.091	0.039*
Prediabetes plus diabetes (n, %)	73 (74.5%)	83 (84.7%)	86 (87.8%)	0.039*	43 (95.6%)	44 (97.8%)	43 (97.7%)	0.779	<0.001 [†]

* p<0.05, [†]p<0.001, § P-value for difference between MHAO and MUAO.

All percentages are column percentage; except for percentages, all values are mean \pm s.d. .

Abbreviations: 2-h PG, 2-hour plasma glucose; BMI, body mass index; HDL, high-density lipoprotein; IL-17, intrahepatic triglyceride; LDL, low-density lipoprotein cholesterol; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OGTT, oral glucose tolerance test.

Table 2. Adjusted odds ratios (ORs) with associated 95% confidence interval (CI) of MUAO, NAFLD and IHTG content for prediabetes plus diabetes.

Variables	Prediabetes plus Diabetes		
	OR	95% CI	P-value
All subjects			
MUAO v.s. MHAO	10.90	3.15 - 37.69	<0.001*
NAFLD v.s. Non-NAFLD	3.02	1.47 - 6.20	0.003*
IHTG content (%) †	1.62	1.07 - 2.46	0.024*
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	1.81	0.86 - 3.81	0.117
Tertile 3	3.13	1.28 - 7.61	0.012*
Trend test			0.011*
Interaction test			
MUAO*NAFLD			0.956
MUAO*Tertiles of IHTG			0.869
MHAO subjects			
NAFLD v.s. Non-NAFLD	2.65	1.25 - 5.60	0.011*
IHTG content (%) †	1.55	1.00 - 2.40	0.051
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	2.31	1.03 - 5.17	0.042*
Tertile 3	2.81	1.14 - 6.90	0.024*
Trend test			0.021*
MUAO subjects			
NAFLD v.s. Non-NAFLD	4.77	0.07 - 327.48	0.469
IHTG content (%) †	0.81	0.13 - 5.26	0.830
IHTG content tertiles ‡			
Tertile 1	1.00		
Tertile 2	3.22	0.24 - 43.54	0.378
Tertile 3	1.90	0.15 - 23.69	0.620
Trend test			0.558

*p<0.05

† OR and 95%CI was expressed by per SD increase of IHTG content.

‡ OR and 95%CI was expressed by the first quartile of IHTG content as the reference.

Abbreviations: CI, confidence interval; IHTG, intrahepatic triglyceride; MHAO, metabolically healthy abdominal obesity; MUAO, metabolically unhealthy abdominal obesity; NAFLD, non-alcoholic fatty liver disease; OR, odds ratio;

OR was adjusted for age, sex, educational level, ever smoking, ever drinking, physical

activity, BMI, systolic and diastolic BP, triglyceride, total cholesterol, HDL- and LDL-
cholesterol and serum uric acid.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Study subjects' selection diagram.

Figure 1. Study subjects' selection diagram.

209x296mm (400 x 400 DPI)

Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.




Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.




Figure 2A. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MHAO subjects.

Figure 2B. Prevalence rates (%) of prediabetes and diabetes stratified by Tertiles of IHTG content in MUAO subjects.

209x296mm (400 x 400 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	5
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-9
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	10
		(c) Explain how missing data were addressed	NA
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	12
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12
		(b) Indicate number of participants with missing data for each variable of interest	NA
Outcome data	15*	Report numbers of outcome events or summary measures	12-13
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	13-14

		(b) Report category boundaries when continuous variables were categorized	13-14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13-14
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-18
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	19
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	19
Generalisability	21	Discuss the generalisability (external validity) of the study results	19
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.